Evidence labels explain what kind of source is being read.
Dictionary / Evidence method
Insufficient evidence
A valid conclusion when sources are absent, too narrow, inconsistent, or indirect.
Evidence methodterm category
0related public pages
editorial navigationdefinition status
draftreview status
635exact evidence rows
487exact source links
0nearby evidence rows
0nearby source links
0do-not-confuse links
0entity links
This page is a dictionary definition and navigation aid. Exact evidence rows below come from approved workbench claims; broader claims and citations live on the related source-backed pages.
Dictionary Reader Map
Use the definition as a doorway, not a conclusion.
Insufficient evidence explains vocabulary used across the cannabinoid encyclopedia. The definition orients the reader; exact rows and related pages carry the source-backed claims.
487 direct sources linked to approved workbench claims. PubMed 34468204
0 nearby evidence rows and 0 nearby source links.
Aliases help readers find the same concept without changing the evidence standard.
Plain-Language Definition
What it means here
Insufficient evidence is used in this encyclopedia as a evidence method term. A valid conclusion when sources are absent, too narrow, inconsistent, or indirect.
Evidence-method terms describe how a source should be read. They help separate human trials, observational work, preclinical work, mechanistic studies, and explicit evidence gaps.
Also searched as: limited evidence, not enough evidence, unclear evidence.
Evidence Guardrail
How to read it without overreaching
Use this term to classify the kind of evidence, not to inflate it. A stronger-sounding label still needs source details, study context, outcome measures, and limits.
Evidence Lens
What this term can currently point to
Direct approved claim rows linked to this dictionary term. PubMed 34468204
Distinct source records under those exact rows. PubMed 34468204
Source-backed public pages where this vocabulary is likely useful.
Evidence rows available on those related public pages.
Exact rows are direct evidence links. Use them first, then use related pages to understand the broader research context.
Source Path
How to move from this definition to research
- Read the definition.Use it to understand the vocabulary in plain English.
- Check exact rows.When direct rows exist, open the linked PubMed or DOI record. PubMed 34468204
- Open related pages.Use nearby pages for broader source-backed context.
- Keep the boundary.A method label describes evidence type; it does not make the evidence stronger.
Exact Evidence Rows
Approved source-backed rows linked to this term
635 exact rows
No matching evidence rows.
Evidence Group
Insufficient
635 exact rows / 487 sources
Evidence row 1 / evidence context
CBN associated with sleep-promoting claims in the pre-2021 evidence base.
insufficient / moderate confidence.
Cannabinol and Sleep: Separating Fact from Fiction PubMed 34468204
Evidence class is insufficient.
Evidence row 19 / evidence context
CBN studied for Sleep.
insufficient / very_low confidence.
Using Cannabis and CBD to Sleep: An Updated Review. PubMed 39612156
Evidence class is insufficient.
Evidence row 20 / evidence context
CBN studied for Sleep.
insufficient / very_low confidence.
Cannabinol (CBN; 30 and 300 mg) effects on sleep and next-day function in insomnia disorder ('CUPID' study): protocol for a randomised, double-blind, placebo-controlled, cross-over, three-arm, proof-of-concept trial. PubMed 37612115
Evidence class is insufficient.
Evidence row 21 / evidence context
CBN studied for Sleep.
insufficient / very_low confidence.
Cannabinoids, Insomnia, and Other Sleep Disorders. PubMed 35537535
Evidence class is insufficient.
Evidence row 22 / evidence context
CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes.
insufficient / very_low confidence.
Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. PubMed 36206805
Evidence class is insufficient.
Evidence row 23 / evidence context
CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes.
insufficient / very_low confidence.
Cannabidiol's impact on drug-metabolization. PubMed 37541924
Evidence class is insufficient.
Evidence row 24 / evidence context
CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes.
insufficient / very_low confidence.
A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication. PubMed 35156171
Evidence class is insufficient.
Evidence row 25 / evidence context
THC associated with driving impairment or safety-relevant performance outcomes.
insufficient / very_low confidence.
Determining the magnitude and duration of acute Δ9-tetrahydrocannabinol (Δ9-THC)-induced driving and cognitive impairment: A systematic and meta-analytic review. PubMed 33497784
Evidence class is insufficient.
Evidence row 26 / evidence context
THC associated with driving impairment or safety-relevant performance outcomes.
insufficient / very_low confidence.
Cannabis and driving ability. PubMed 33839427
Evidence class is insufficient.
Evidence row 27 / evidence context
THC associated with driving impairment or safety-relevant performance outcomes.
insufficient / very_low confidence.
Association of driving with blood delta-9-tetrahydrocannabinol: a systematic review. PubMed 40172477
Evidence class is insufficient.
Evidence row 30 / evidence context
CBD studied for Anxiety-related outcomes.
insufficient / very_low confidence.
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. PubMed 33424664
Evidence class is insufficient.
Evidence row 31 / evidence context
CBG studied for Pain-related outcomes.
insufficient / very_low confidence.
Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential. PubMed 39598860
Evidence class is insufficient.
Evidence row 32 / evidence context
CBG studied for Pain-related outcomes.
insufficient / very_low confidence.
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. PubMed 21749363
Evidence class is insufficient.
Evidence row 34 / evidence context
CBC studied for Inflammation-related outcomes.
insufficient / very_low confidence.
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. PubMed 21749363
Evidence class is insufficient.
Evidence row 38 / evidence context
THCV studied for Appetite and metabolic outcomes.
insufficient / very_low confidence.
The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management. PubMed 40270953
Evidence class is insufficient.
Evidence row 39 / evidence context
THCV studied for Appetite and metabolic outcomes.
insufficient / very_low confidence.
It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets. PubMed 32899626
Evidence class is insufficient.
Evidence row 40 / evidence context
CBDV studied for Seizure and neurodevelopmental outcomes.
insufficient / very_low confidence.
Therapeutic potential of cannabidivarin for epilepsy and autism spectrum disorder. PubMed 33895189
Evidence class is insufficient.
Evidence row 41 / evidence context
CBDV studied for Seizure and neurodevelopmental outcomes.
insufficient / very_low confidence.
Cannabis sativa: Much more beyond Δ9-tetrahydrocannabinol. PubMed 32335286
Evidence class is insufficient.
Evidence row 42 / evidence context
CBDV studied for Seizure and neurodevelopmental outcomes.
insufficient / very_low confidence.
Cannabinoids for People with ASD: A Systematic Review of Published and Ongoing Studies. PubMed 32825313
Evidence class is insufficient.
Evidence row 43 / evidence context
CBDA studied for nausea-related or inflammation-related outcomes.
insufficient / very_low confidence.
Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer. PubMed 30627539
Evidence class is insufficient.
Evidence row 45 / evidence context
THCA studied for THCA-specific safety, effect, or mechanism claims.
insufficient / very_low confidence.
Investigational cannabinoids in seizure disorders, what have we learned thus far? PubMed 29842819
Evidence class is insufficient.
Evidence row 48 / evidence context
CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes.
insufficient / very_low confidence.
Memantine for autism spectrum disorder. PubMed 36006807
Evidence class is insufficient.
Evidence row 49 / evidence context
CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes.
insufficient / very_low confidence.
Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. PubMed 39007525
Evidence class is insufficient.
Evidence row 50 / evidence context
CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes.
insufficient / very_low confidence.
Antiseizure medications for Lennox-Gastaut Syndrome: Comprehensive review and proposed consensus treatment algorithm. PubMed 39854828
Evidence class is insufficient.
Evidence row 51 / evidence context
CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes.
insufficient / very_low confidence.
Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. PubMed 31288397
Evidence class is insufficient.
Evidence row 52 / evidence context
CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes.
insufficient / very_low confidence.
Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs. PubMed 32918835
Evidence class is insufficient.
Evidence row 53 / evidence context
THC associated with driving impairment or safety-relevant performance outcomes.
insufficient / very_low confidence.
Pharmacotherapies for cannabis use disorder. PubMed 41025421
Evidence class is insufficient.
Evidence row 54 / evidence context
THC associated with driving impairment or safety-relevant performance outcomes.
insufficient / very_low confidence.
Mechanisms of cannabis impairment: Implications for modeling driving performance. PubMed 34634690
Evidence class is insufficient.
Evidence row 55 / evidence context
THC associated with driving impairment or safety-relevant performance outcomes.
insufficient / very_low confidence.
Prescribing medicinal cannabis. PubMed 33093741
Evidence class is insufficient.
Evidence row 56 / evidence context
THC associated with driving impairment or safety-relevant performance outcomes.
insufficient / very_low confidence.
Driving Impairment Cases Involving Etizolam and Flubromazolam. PubMed 32399568
Evidence class is insufficient.
Evidence row 58 / evidence context
CBD studied for Anxiety-related outcomes.
insufficient / very_low confidence.
Therapeutic Use of Cannabis and Cannabinoids: A Review. PubMed 41296368
Evidence class is insufficient.
Evidence row 61 / evidence context
CBD studied for Anxiety-related outcomes.
insufficient / very_low confidence.
Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. PubMed 35982439
Evidence class is insufficient.
Evidence row 64 / evidence context
CBG studied for Pain-related outcomes.
insufficient / very_low confidence.
The Effects of Cannabinoids on Pro- and Anti-Inflammatory Cytokines: A Systematic Review of In Vivo Studies. PubMed 33998900
Evidence class is insufficient.
Evidence row 67 / evidence context
CBG studied for Pain-related outcomes.
insufficient / very_low confidence.
Applications of Cannabinoids in Neuropathic Pain: An Updated Review. PubMed 37824417
Evidence class is insufficient.
Evidence row 68 / evidence context
CBG studied for Pain-related outcomes.
insufficient / very_low confidence.
Acidic Cannabinoids Suppress Proinflammatory Cytokine Release by Blocking Store-operated Calcium Entry. PubMed 35910331
Evidence class is insufficient.
Evidence row 69 / evidence context
CBG studied for Pain-related outcomes.
insufficient / very_low confidence.
Cannabinoids and Opioids in the Treatment of Inflammatory Bowel Diseases. PubMed 31899693
Evidence class is insufficient.
Evidence row 70 / evidence context
CBG studied for Pain-related outcomes.
insufficient / very_low confidence.
Therapeutic potential of acidic cannabinoids: an update. PubMed 41545891
Evidence class is insufficient.
Evidence row 71 / evidence context
CBC studied for Inflammation-related outcomes.
insufficient / very_low confidence.
Therapeutic potential of acidic cannabinoids: an update. PubMed 41545891
Evidence class is insufficient.
Evidence row 78 / evidence context
THCV studied for Appetite and metabolic outcomes.
insufficient / very_low confidence.
CB₁-independent mechanisms of Δ⁹-THCV, AM251 and SR141716 (rimonabant). PubMed 21740450
Evidence class is insufficient.
Evidence row 84 / evidence context
CBDV studied for Seizure and neurodevelopmental outcomes.
insufficient / very_low confidence.
Efficacy and Safety of Cannabinoid-Based Products in Children and Adolescents with Autism Spectrum Disorder, Fragile X Syndrome and Rett Syndrome: A Systematic Review. PubMed 42339654
Evidence class is insufficient.
Evidence row 85 / evidence context
CBDV studied for Seizure and neurodevelopmental outcomes.
insufficient / very_low confidence.
Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders? PubMed 33613289
Evidence class is insufficient.
Evidence row 87 / evidence context
THCA studied for THCA-specific safety, effect, or mechanism claims.
insufficient / very_low confidence.
Semiquantitative Screening of THC Analogues by Silica Gel TLC with an Ag(I) Retention Zone and Chromogenic Smartphone Detection. PubMed 36178203
Evidence class is insufficient.
Evidence row 90 / evidence context
THCA studied for THCA-specific safety, effect, or mechanism claims.
insufficient / very_low confidence.
Identification and Quantification of the Main Psychoactive Ingredients of Cannabis in Urine Using Excitation-Eemission Matrix Fluorescence Coupled with Parallel Factor Analysis. PubMed 37810707
Evidence class is insufficient.
Evidence row 91 / evidence context
THCA studied for THCA-specific safety, effect, or mechanism claims.
insufficient / very_low confidence.
Ultrafast, Selective, and Highly Sensitive Nonchromatographic Analysis of Fourteen Cannabinoids in Cannabis Extracts, Δ8-Tetrahydrocannabinol Synthetic Mixtures, and Edibles by Cyclic Ion Mobility Spectrometry-Mass Spectrometry. PubMed 38862388
Evidence class is insufficient.
Evidence row 92 / evidence context
THCA studied for THCA-specific safety, effect, or mechanism claims.
insufficient / very_low confidence.
Quality Control of Traditional Cannabis Tinctures: Pattern, Markers, and Stability. PubMed 28117322
Evidence class is insufficient.
Evidence row 93 / evidence context
Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Pharmacologic treatment of fibromyalgia: an update. PubMed 41142233
Evidence class is insufficient.
Evidence row 94 / evidence context
Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
The safety of studies with intravenous Δ⁹-tetrahydrocannabinol in humans, with case histories. PubMed 21845389
Evidence class is insufficient.
Evidence row 95 / evidence context
Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabis-based medicines for chronic neuropathic pain in adults. PubMed 41548880
Evidence class is insufficient.
Evidence row 96 / evidence context
Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Psychedelic use in individuals living with eating disorders or disordered eating: findings from the international MED-FED survey. PubMed 40708053
Evidence class is insufficient.
Evidence row 98 / evidence context
CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts.
insufficient / very_low confidence.
Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. PubMed 37648266
Evidence class is insufficient.
Evidence row 99 / evidence context
THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts.
insufficient / very_low confidence.
High Stakes: Exploring the Impact of Cannabis Use in Pregnancy and Lactation. PubMed 40164212
Evidence class is insufficient.
Evidence row 100 / evidence context
Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts.
insufficient / very_low confidence.
Pharmacokinetics of Cannabis and Its Derivatives in Animals and Humans During Pregnancy and Breastfeeding. PubMed 35903331
Evidence class is insufficient.
Evidence row 101 / evidence context
THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts.
insufficient / very_low confidence.
Risks of Cannabinoid Exposure on Birth Outcomes: A Systematic Review. PubMed 40589083
Evidence class is insufficient.
Evidence row 102 / evidence context
Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts.
insufficient / very_low confidence.
Management of Pediatric Cannabinoid Hyperemesis Syndrome: A Review. PubMed 34035677
Evidence class is insufficient.
Evidence row 104 / evidence context
Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts.
insufficient / very_low confidence.
Cannabis Use in Pregnancy and Neonatal Outcomes: A Systematic Review and Meta-Analysis. PubMed 36730710
Evidence class is insufficient.
Evidence row 106 / evidence context
THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts.
insufficient / very_low confidence.
Association of Cannabis with Apneic Episodes in a Breastfed Infant: A Case Study. PubMed 38469628
Evidence class is insufficient.
Evidence row 109 / evidence context
CBDV studied for Seizure and neurodevelopmental outcomes.
insufficient / very_low confidence.
Investigational cannabinoids in seizure disorders, what have we learned thus far? PubMed 29842819
Evidence class is insufficient.
Evidence row 111 / evidence context
CBDV studied for Seizure and neurodevelopmental outcomes.
insufficient / very_low confidence.
Phytocannabinoids and epilepsy. PubMed 25475762
Evidence class is insufficient.
Evidence row 114 / evidence context
CBDV studied for Seizure and neurodevelopmental outcomes.
insufficient / very_low confidence.
Antiepileptic Drugs in Clinical Development: Differentiate or Die? PubMed 28799516
Evidence class is insufficient.
Evidence row 115 / evidence context
CBDV studied for Seizure and neurodevelopmental outcomes.
insufficient / very_low confidence.
The potential role of cannabinoids in epilepsy treatment. PubMed 28845714
Evidence class is insufficient.
Evidence row 117 / evidence context
CBDV studied for Seizure and neurodevelopmental outcomes.
insufficient / very_low confidence.
Cannabinoids for epilepsy: What do we know and where do we go? PubMed 29214639
Evidence class is insufficient.
Evidence row 123 / evidence context
CBDV studied for Seizure and neurodevelopmental outcomes.
insufficient / very_low confidence.
Therapeutic potential of minor cannabinoids in psychiatric disorders: A systematic review. PubMed 39541799
Evidence class is insufficient.
Evidence row 125 / evidence context
CBDA studied for nausea-related or inflammation-related outcomes.
insufficient / very_low confidence.
Therapeutic potential of acidic cannabinoids: an update. PubMed 41545891
Evidence class is insufficient.
Evidence row 126 / evidence context
CBDA studied for nausea-related or inflammation-related outcomes.
insufficient / very_low confidence.
Therapeutic Potential of Cannabidiol, Cannabidiolic Acid, and Cannabidiolic Acid Methyl Ester as Treatments for Nausea and Vomiting. PubMed 34115951
Evidence class is insufficient.
Evidence row 136 / evidence context
CBDA studied for nausea-related or inflammation-related outcomes.
insufficient / very_low confidence.
Short term feeding of industrial hemp with a high cannabidiolic acid (CBDA) content increases lying behavior and reduces biomarkers of stress and inflammation in Holstein steers. PubMed 35256692
Evidence class is insufficient.
Evidence row 139 / evidence context
CBDA studied for nausea-related or inflammation-related outcomes.
insufficient / very_low confidence.
Medical Cannabis Use and Inflammatory Cytokines and Chemokines Among Adult Chronic Pain Patients. PubMed 36342776
Evidence class is insufficient.
Evidence row 140 / evidence context
CBDA studied for nausea-related or inflammation-related outcomes.
insufficient / very_low confidence.
Raman-Based Differentiation of Hemp, Cannabidiol-Rich Hemp, and Cannabis. PubMed 32401504
Evidence class is insufficient.
Evidence row 141 / evidence context
CBDA studied for nausea-related or inflammation-related outcomes.
insufficient / very_low confidence.
Serum cannabidiol, tetrahydrocannabinol (THC), and their native acid derivatives after transdermal application of a low-THC Cannabis sativa extract in beagles. PubMed 32735381
Evidence class is insufficient.
Evidence row 142 / evidence context
CBDA studied for nausea-related or inflammation-related outcomes.
insufficient / very_low confidence.
Phytochemical Analysis of the Methanolic Extract and Essential Oil from Leaves of Industrial Hemp Futura 75 Cultivar: Isolation of a New Cannabinoid Derivative and Biological Profile Using Computational Approaches. PubMed 35807623
Evidence class is insufficient.
Evidence row 144 / evidence context
CBDA studied for nausea-related or inflammation-related outcomes.
insufficient / very_low confidence.
(‒)-Cannabidiolic Acid, a Still Overlooked Bioactive Compound: An Introductory Review and Preliminary Research. PubMed 32517131
Evidence class is insufficient.
Evidence row 145 / evidence context
CBDA studied for nausea-related or inflammation-related outcomes.
insufficient / very_low confidence.
Effects of Cannabidiol on Locomotor Activity. PubMed 35629320
Evidence class is insufficient.
Evidence row 147 / evidence context
CBDA studied for nausea-related or inflammation-related outcomes.
insufficient / very_low confidence.
Synergy between cannabidiol, cannabidiolic acid, and Δ⁹-tetrahydrocannabinol in the regulation of emesis in the Suncus murinus (house musk shrew). PubMed 26030435
Evidence class is insufficient.
Evidence row 148 / evidence context
CBDA studied for nausea-related or inflammation-related outcomes.
insufficient / very_low confidence.
Alginate-based microencapsulation as a strategy to improve the therapeutic potential of cannabidiolic acid. PubMed 39667593
Evidence class is insufficient.
Evidence row 150 / evidence context
Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Self-reported adverse events associated with ∆8-Tetrahydrocannabinol (Delta-8-THC) Use. PubMed 37217977
Evidence class is insufficient.
Evidence row 151 / evidence context
Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and Cannabis. PubMed 38868665
Evidence class is insufficient.
Evidence row 152 / evidence context
Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Evaluating Delta-8-THC-Induced Psychosis: A Systematic Review. PubMed 39805119
Evidence class is insufficient.
Evidence row 153 / evidence context
Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Prevalence of carboxy-Δ8-tetrahydrocannabiniol in antidoping samples. PubMed 38176407
Evidence class is insufficient.
Evidence row 154 / evidence context
Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Delta-8, a Cannabis-Derived Tetrahydrocannabinol Isomer: Evaluating Case Report Data in the Food and Drug Administration Adverse Event Reporting System (FAERS) Database. PubMed 36742440
Evidence class is insufficient.
Evidence row 158 / evidence context
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabinoids in clinical practice. PubMed 11152013
Evidence class is insufficient.
Evidence row 160 / evidence context
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Comprehensive mini-review: therapeutic potential of cannabigerol - focus on the cardiovascular system. PubMed 40206058
Evidence class is insufficient.
Evidence row 166 / evidence context
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
The Potential of Cannabichromene (CBC) as a Therapeutic Agent. PubMed 38777605
Evidence class is insufficient.
Evidence row 167 / evidence context
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management. PubMed 40872492
Evidence class is insufficient.
Evidence row 168 / evidence context
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review. PubMed 37630401
Evidence class is insufficient.
Evidence row 170 / evidence context
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
A systematic review of analytical methodologies capable of analysing phytocannabinoids in cosmetics. PubMed 38229238
Evidence class is insufficient.
Evidence row 173 / evidence context
CBC studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
CBD, a precursor of THC in e-cigarettes. PubMed 33903673
Evidence class is insufficient.
Evidence row 175 / evidence context
CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts.
insufficient / very_low confidence.
Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. PubMed 36206805
Evidence class is insufficient.
Evidence row 176 / evidence context
CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts.
insufficient / very_low confidence.
Therapeutic Use of Cannabis and Cannabinoids: A Review. PubMed 41296368
Evidence class is insufficient.
Evidence row 177 / evidence context
THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts.
insufficient / very_low confidence.
Cannabis use during pregnancy: Pharmacokinetics and effects on child development. PubMed 28847562
Evidence class is insufficient.
Evidence row 178 / evidence context
THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts.
insufficient / very_low confidence.
Impact of cannabinoids on pregnancy, reproductive health, and offspring outcomes. PubMed 35662548
Evidence class is insufficient.
Evidence row 179 / evidence context
THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts.
insufficient / very_low confidence.
Cannabis and synaptic reprogramming of the developing brain. PubMed 34021274
Evidence class is insufficient.
Evidence row 180 / evidence context
Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts.
insufficient / very_low confidence.
Long-term Cognitive, Psychological, and Health Outcomes Associated With Child Abuse and Neglect. PubMed 32943535
Evidence class is insufficient.
Evidence row 181 / evidence context
Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts.
insufficient / very_low confidence.
[Consequences of tobacco, cocaine and cannabis consumption during pregnancy on the pregnancy itself, on the newborn and on child development: A review]. PubMed 25439854
Evidence class is insufficient.
Evidence row 182 / evidence context
Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts.
insufficient / very_low confidence.
Smoke Alarm. PubMed 37651516
Evidence class is insufficient.
Evidence row 184 / evidence context
Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts.
insufficient / very_low confidence.
Maternal cannabis use in pregnancy, perinatal outcomes, and cognitive development in offspring: a longitudinal analysis of the ALSPAC cohort using paternal cannabis use as a negative control exposure. PubMed 40353977
Evidence class is insufficient.
Evidence row 185 / evidence context
Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts.
insufficient / very_low confidence.
Longitudinal Associations Between Cannabis Use during Pregnancy and Child Cognitive, Motor, and Language Development at 2 Years Old. PubMed 40121379
Evidence class is insufficient.
Evidence row 188 / evidence context
CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts.
insufficient / very_low confidence.
Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome. PubMed 33754312
Evidence class is insufficient.
Evidence row 189 / evidence context
Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts.
insufficient / very_low confidence.
An Overview of Cannabinoid Interactions With Common Pediatric Antineoplastic Agents. PubMed 42057496
Evidence class is insufficient.
Evidence row 190 / evidence context
Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts.
insufficient / very_low confidence.
Marijuana and the Pediatric Population. PubMed 32661188
Evidence class is insufficient.
Evidence row 192 / evidence context
CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts.
insufficient / very_low confidence.
Pediatric Concerns Due to Expanded Cannabis Use: Unintended Consequences of Legalization. PubMed 27139708
Evidence class is insufficient.
Evidence row 193 / evidence context
CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts.
insufficient / very_low confidence.
Recreational Cannabis Use During Human Pregnancy: Its Effects on the Placenta and Endocannabinoid System. PubMed 41683846
Evidence class is insufficient.
Evidence row 194 / evidence context
CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts.
insufficient / very_low confidence.
Cannabinoid Signalling in Immune-Reproductive Crosstalk during Human Pregnancy. PubMed 33800053
Evidence class is insufficient.
Evidence row 195 / evidence context
Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts.
insufficient / very_low confidence.
Cannabis for morning sickness: areas for intervention to decrease cannabis consumption during pregnancy. PubMed 37330589
Evidence class is insufficient.
Evidence row 196 / evidence context
CBD studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. PubMed 30374683
Evidence class is insufficient.
Evidence row 197 / evidence context
CBD studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Update on Cannabidiol in Drug-Resistant Epilepsy. PubMed 39585547
Evidence class is insufficient.
Evidence row 198 / evidence context
CBD studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment. PubMed 31802404
Evidence class is insufficient.
Evidence row 199 / evidence context
CBD studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy. PubMed 33667843
Evidence class is insufficient.
Evidence row 200 / evidence context
CBD studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access program. PubMed 37593907
Evidence class is insufficient.
Evidence row 201 / evidence context
THC studied for receptor, target, or pharmacology mechanisms.
insufficient / very_low confidence.
Development and Validation of a GC-FID Method for the Quantitation of 20 Different Acidic and Neutral Cannabinoids. PubMed 36257598
Evidence class is insufficient.
Evidence row 204 / evidence context
THC modulates receptor, target, or pharmacology mechanisms.
insufficient / very_low confidence.
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. PubMed 17828291
Evidence class is insufficient.
Evidence row 205 / evidence context
THC modulates receptor, target, or pharmacology mechanisms.
insufficient / very_low confidence.
Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. PubMed 25220897
Evidence class is insufficient.
Evidence row 206 / evidence context
Cannabinoids modulates receptor, target, or pharmacology mechanisms.
insufficient / very_low confidence.
Cannabinoid receptor 2 (CB2) modulators: A patent review (2016-2024). PubMed 39288632
Evidence class is insufficient.
Evidence row 208 / evidence context
Cannabinoids modulates receptor, target, or pharmacology mechanisms.
insufficient / very_low confidence.
Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists. PubMed 18537620
Evidence class is insufficient.
Evidence row 209 / evidence context
Endocannabinoids modulates receptor, target, or pharmacology mechanisms.
insufficient / very_low confidence.
Potential metabolic and behavioural roles of the putative endocannabinoid receptors GPR18, GPR55 and GPR119 in feeding. PubMed 31146657
Evidence class is insufficient.
Evidence row 210 / evidence context
Endocannabinoids modulates receptor, target, or pharmacology mechanisms.
insufficient / very_low confidence.
Some Prospective Alternatives for Treating Pain: The Endocannabinoid System and Its Putative Receptors GPR18 and GPR55. PubMed 30670965
Evidence class is insufficient.
Evidence row 211 / evidence context
Cannabinoids modulates receptor, target, or pharmacology mechanisms.
insufficient / very_low confidence.
Cannabinoid Receptor-Related Orphan G Protein-Coupled Receptors. PubMed 28826536
Evidence class is insufficient.
Evidence row 212 / evidence context
Cannabinoids modulates receptor, target, or pharmacology mechanisms.
insufficient / very_low confidence.
New Insights in Cannabinoid Receptor Structure and Signaling. PubMed 30767756
Evidence class is insufficient.
Evidence row 214 / evidence context
THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms.
insufficient / very_low confidence.
Cannabinoid Ligands Targeting TRP Channels. PubMed 30697147
Evidence class is insufficient.
Evidence row 215 / evidence context
CBD modulates TRP channel activity or ionotropic cannabinoid target mechanisms.
insufficient / very_low confidence.
An Analysis of the Putative CBD Binding Site in the Ionotropic Cannabinoid Receptors. PubMed 33362478
Evidence class is insufficient.
Evidence row 217 / evidence context
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. PubMed 37648266
Evidence class is insufficient.
Evidence row 218 / evidence context
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabis Use and the Risk for Psychosis and Affective Disorders. PubMed 31647377
Evidence class is insufficient.
Evidence row 219 / evidence context
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Relationships between cannabis use and mental disorders: assessing the coherence of evidence from studies with different methodologies. PubMed 42309106
Evidence class is insufficient.
Evidence row 220 / evidence context
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabis and psychiatric disorders. PubMed 20562767
Evidence class is insufficient.
Evidence row 222 / evidence context
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Role of cannabis in cardiovascular disorders. PubMed 28840009
Evidence class is insufficient.
Evidence row 226 / evidence context
CBD modulates endocannabinoid enzyme activity or metabolic mechanisms.
insufficient / very_low confidence.
Short-term repeated oral intake of low dose cannabidiol: effects on liver enzyme activity and creatinine concentration during intense exercise. PubMed 39630203
Evidence class is insufficient.
Evidence row 228 / evidence context
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Pharmacotherapies for cannabis use disorder. PubMed 41025421
Evidence class is insufficient.
Evidence row 229 / evidence context
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Clinical management of cannabis withdrawal. PubMed 34791767
Evidence class is insufficient.
Evidence row 230 / evidence context
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. PubMed 35510826
Evidence class is insufficient.
Evidence row 231 / evidence context
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
The differential effects of medicinal cannabis on mental health: A systematic review. PubMed 40186931
Evidence class is insufficient.
Evidence row 232 / evidence context
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Product labeling accuracy and contamination analysis of commercially available cannabidiol product samples. PubMed 38562466
Evidence class is insufficient.
Evidence row 234 / evidence context
Cannabinoids studied for Cannabinoids and nausea/vomiting research outcomes.
insufficient / very_low confidence.
Diagnosis and Management of Cyclic Vomiting Syndrome: A Critical Review. PubMed 36791365
Evidence class is insufficient.
Evidence row 235 / evidence context
Cannabinoids studied for Cannabinoids and nausea/vomiting research outcomes.
insufficient / very_low confidence.
Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline. PubMed 38478773
Evidence class is insufficient.
Evidence row 236 / evidence context
Cannabinoids studied for Cannabinoids and nausea/vomiting research outcomes.
insufficient / very_low confidence.
Cannabinoids for nausea and vomiting related to chemotherapy: Overview of systematic reviews. PubMed 29168289
Evidence class is insufficient.
Evidence row 237 / evidence context
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabinoids and monoaminergic system: implications for learning and memory. PubMed 39206116
Evidence class is insufficient.
Evidence row 239 / evidence context
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Prenatal cannabinoid exposure and altered neurotransmission. PubMed 30771373
Evidence class is insufficient.
Evidence row 240 / evidence context
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Acute and Chronic Effects of Cannabinoids on Human Cognition-A Systematic Review. PubMed 26858214
Evidence class is insufficient.
Evidence row 241 / evidence context
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Endocannabinoid signaling and long-term synaptic plasticity. PubMed 19575681
Evidence class is insufficient.
Evidence row 242 / evidence context
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabinoids for Dermatological Applications: Mechanistic Insights, Clinical Evidence, and Emerging Nanotechnology-Enabled Delivery Strategies. PubMed 42076122
Evidence class is insufficient.
Evidence row 244 / evidence context
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
[Not all drugs are the same]. PubMed 23974649
Evidence class is insufficient.
Evidence row 245 / evidence context
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Brands of Intoxicating Cannabis Products in Vape Shops: United States, 2023. PubMed 41324909
Evidence class is insufficient.
Evidence row 246 / evidence context
CBD studied for Rare phytocannabinoids research topics.
insufficient / very_low confidence.
Calculated and experimental 1 H and 13 C NMR assignments for cannabicitran. PubMed 34617621
Evidence class is insufficient.
Evidence row 247 / evidence context
HHC studied for Rare phytocannabinoids research topics.
insufficient / very_low confidence.
Isolation and Characterization of Impurities in Commercially Marketed Δ8-THC Products. PubMed 36827690
Evidence class is insufficient.
Evidence row 248 / evidence context
CBG studied for Rare phytocannabinoids research topics.
insufficient / very_low confidence.
Cannabigerol and Cannabicyclol Block SARS-CoV-2 Cell Fusion. PubMed 38885660
Evidence class is insufficient.
Evidence row 249 / evidence context
THC studied for Rare phytocannabinoids research topics.
insufficient / very_low confidence.
Synthetic Strategies for Rare Cannabinoids Derived from Cannabis sativa. PubMed 35648593
Evidence class is insufficient.
Evidence row 250 / evidence context
THC studied for Rare phytocannabinoids research topics.
insufficient / very_low confidence.
Chiral Separation of Cannabichromene, Cannabicyclol, and Their Acidic Analogs on Polysaccharide Chiral Stationary Phases. PubMed 36770831
Evidence class is insufficient.
Evidence row 251 / evidence context
CBC studied for Rare phytocannabinoids research topics.
insufficient / very_low confidence.
Cannabichromene Racemization and Absolute Stereochemistry Based on a Cannabicyclol Analog. PubMed 34078070
Evidence class is insufficient.
Evidence row 252 / evidence context
THC studied for Rare phytocannabinoids research topics.
insufficient / very_low confidence.
A new HPLC method with multiple detection systems for impurity analysis and discrimination of natural versus synthetic cannabidiol. PubMed 38940871
Evidence class is insufficient.
Evidence row 253 / evidence context
CBD modulates receptor, target, or pharmacology mechanisms.
insufficient / very_low confidence.
Differential contribution of CB1, CB2, 5-HT1A, and PPAR-γ receptors to cannabidiol effects on ischemia-induced emotional and cognitive impairments. PubMed 33522084
Evidence class is insufficient.
Evidence row 255 / evidence context
CBD modulates receptor, target, or pharmacology mechanisms.
insufficient / very_low confidence.
A novel insight into the antidepressant effect of cannabidiol: possible involvement of the 5-HT1A, CB1, GPR55, and PPARγ receptors. PubMed 39657242
Evidence class is insufficient.
Evidence row 256 / evidence context
CBD modulates receptor, target, or pharmacology mechanisms.
insufficient / very_low confidence.
Cannabidiol: Pharmaceutical formulations and biomedical applications. PubMed 42212209
Evidence class is insufficient.
Evidence row 258 / evidence context
Endocannabinoids modulates receptor, target, or pharmacology mechanisms.
insufficient / very_low confidence.
Cys-loop receptors on cannabinoids: All high? PubMed 36439263
Evidence class is insufficient.
Evidence row 259 / evidence context
Cannabinoids modulates receptor, target, or pharmacology mechanisms.
insufficient / very_low confidence.
Allosteric modulation of glycine receptors. PubMed 21557733
Evidence class is insufficient.
Evidence row 264 / evidence context
Cannabinoids modulates receptor, target, or pharmacology mechanisms.
insufficient / very_low confidence.
Sampling glutamate and GABA with microdialysis: suggestions on how to get the dialysis membrane closer to the synapse. PubMed 15589342
Evidence class is insufficient.
Evidence row 265 / evidence context
Endocannabinoids modulates receptor, target, or pharmacology mechanisms.
insufficient / very_low confidence.
Cannabinoids in Parkinson's Disease. PubMed 28861502
Evidence class is insufficient.
Evidence row 266 / evidence context
Cannabinoids modulates receptor, target, or pharmacology mechanisms.
insufficient / very_low confidence.
Tolerance to alcohol: A critical yet understudied factor in alcohol addiction. PubMed 33631255
Evidence class is insufficient.
Evidence row 273 / evidence context
THC studied for Cannabinoids and immune modulation research outcomes.
insufficient / very_low confidence.
Pharmacokinetics and pharmacodynamics of cannabinoids. PubMed 12648025
Evidence class is insufficient.
Evidence row 275 / evidence context
Cannabinoids studied for Cannabinoids and immune modulation research outcomes.
insufficient / very_low confidence.
CB2 receptor in the CNS: From immune and neuronal modulation to behavior. PubMed 37164044
Evidence class is insufficient.
Evidence row 276 / evidence context
Cannabinoids studied for Cannabinoids and immune modulation research outcomes.
insufficient / very_low confidence.
Cannabinoid receptor signaling. PubMed 16596771
Evidence class is insufficient.
Evidence row 281 / evidence context
CBD studied for receptor, target, or pharmacology mechanisms.
insufficient / very_low confidence.
Pharmacokinetics of Non-Psychotropic Phytocannabinoids. PubMed 40006604
Evidence class is insufficient.
Evidence row 282 / evidence context
CBCA studied for receptor, target, or pharmacology mechanisms.
insufficient / very_low confidence.
Rapid Antibacterial Activity of Cannabichromenic Acid against Methicillin-Resistant Staphylococcus aureus. PubMed 32824356
Evidence class is insufficient.
Evidence row 283 / evidence context
CBC studied for receptor, target, or pharmacology mechanisms.
insufficient / very_low confidence.
Enhancing Cannabichromenic Acid Biosynthesis in Saccharomyces cerevisiae. PubMed 39808700
Evidence class is insufficient.
Evidence row 284 / evidence context
CBC studied for receptor, target, or pharmacology mechanisms.
insufficient / very_low confidence.
In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters. PubMed 35306000
Evidence class is insufficient.
Evidence row 285 / evidence context
THC studied for receptor, target, or pharmacology mechanisms.
insufficient / very_low confidence.
Bidimensional heart-cut achiral-chiral liquid chromatography coupled to high-resolution mass spectrometry for the separation of the main chiral phytocannabinoids and enantiomerization studies of cannabichromene and cannabichromenic acid. PubMed 37708768
Evidence class is insufficient.
Evidence row 286 / evidence context
THCA studied for receptor, target, or pharmacology mechanisms.
insufficient / very_low confidence.
Comparison of decarboxylation rates of acidic cannabinoids between secretory cavity contents and air-dried inflorescence extracts in Cannabis sativa cv. 'Cherry Wine'. PubMed 39013926
Evidence class is insufficient.
Evidence row 287 / evidence context
THC studied for receptor, target, or pharmacology mechanisms.
insufficient / very_low confidence.
Direct Quantitation of Phytocannabinoids by One-Dimensional 1H qNMR and Two-Dimensional 1H-1H COSY qNMR in Complex Natural Mixtures. PubMed 35566314
Evidence class is insufficient.
Evidence row 288 / evidence context
THC studied for Endocannabinoids and endocannabinoid-like lipids research topics.
insufficient / very_low confidence.
An Introduction to the Endogenous Cannabinoid System. PubMed 26698193
Evidence class is insufficient.
Evidence row 289 / evidence context
THC studied for Endocannabinoids and endocannabinoid-like lipids research topics.
insufficient / very_low confidence.
The Endocannabinoid System and its Modulation by Phytocannabinoids. PubMed 26271952
Evidence class is insufficient.
Evidence row 290 / evidence context
Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics.
insufficient / very_low confidence.
Endocannabinoid Turnover. PubMed 28826539
Evidence class is insufficient.
Evidence row 291 / evidence context
Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics.
insufficient / very_low confidence.
Endocannabinoids. PubMed 9831287
Evidence class is insufficient.
Evidence row 293 / evidence context
THC studied for Endocannabinoids and endocannabinoid-like lipids research topics.
insufficient / very_low confidence.
Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. PubMed 19833407
Evidence class is insufficient.
Evidence row 294 / evidence context
THC studied for Endocannabinoids and endocannabinoid-like lipids research topics.
insufficient / very_low confidence.
Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. PubMed 17704824
Evidence class is insufficient.
Evidence row 295 / evidence context
Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics.
insufficient / very_low confidence.
Classical endocannabinoid-like compounds and their regulation by nutrients. PubMed 24677570
Evidence class is insufficient.
Evidence row 296 / evidence context
Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics.
insufficient / very_low confidence.
Effects of fermentation and alkalisation on the formation of endocannabinoid-like compounds in olives. PubMed 38909454
Evidence class is insufficient.
Evidence row 297 / evidence context
Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics.
insufficient / very_low confidence.
Endocannabinoids, endocannabinoid-like compounds and cortisone in head hair of health care workers as markers of stress and resilience during the early COVID-19 pandemic. PubMed 38296973
Evidence class is insufficient.
Evidence row 298 / evidence context
Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics.
insufficient / very_low confidence.
Roles of Endocannabinoids and Endocannabinoid-Like Molecules in Energy Homeostasis and Metabolic Regulation: A Nutritional Perspective. PubMed 34115519
Evidence class is insufficient.
Evidence row 300 / evidence context
Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms.
insufficient / very_low confidence.
Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases-focusing on FAAH/MAGL inhibitors. PubMed 32203086
Evidence class is insufficient.
Evidence row 302 / evidence context
Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms.
insufficient / very_low confidence.
The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease? PubMed 34217798
Evidence class is insufficient.
Evidence row 303 / evidence context
THC modulates endocannabinoid enzyme activity or metabolic mechanisms.
insufficient / very_low confidence.
FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. PubMed 20047159
Evidence class is insufficient.
Evidence row 304 / evidence context
Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms.
insufficient / very_low confidence.
Potential of Fatty Acid Amide Hydrolase (FAAH), Monoacylglycerol Lipase (MAGL), and Diacylglycerol Lipase (DAGL) Enzymes as Targets for Obesity Treatment: A Narrative Review. PubMed 34959715
Evidence class is insufficient.
Evidence row 308 / evidence context
Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms.
insufficient / very_low confidence.
Critical enzymes involved in endocannabinoid metabolism. PubMed 17346227
Evidence class is insufficient.
Evidence row 309 / evidence context
THC modulates endocannabinoid enzyme activity or metabolic mechanisms.
insufficient / very_low confidence.
Chemical Probes for Investigating the Endocannabinoid System. PubMed 39747798
Evidence class is insufficient.
Evidence row 310 / evidence context
Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms.
insufficient / very_low confidence.
Structural properties and role of the endocannabinoid lipases ABHD6 and ABHD12 in lipid signalling and disease. PubMed 30564946
Evidence class is insufficient.
Evidence row 312 / evidence context
Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms.
insufficient / very_low confidence.
The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors. PubMed 21418147
Evidence class is insufficient.
Evidence row 315 / evidence context
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Marijuana as a trigger of cardiovascular events: speculation or scientific certainty? PubMed 17005273
Evidence class is insufficient.
Evidence row 316 / evidence context
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cardiovascular consequences of marijuana use. PubMed 12412838
Evidence class is insufficient.
Evidence row 317 / evidence context
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Acute Effects of Cannabis Inhalation on Arterial Stiffness, Vascular Endothelial Function, and Cardiac Function. PubMed 39575727
Evidence class is insufficient.
Evidence row 318 / evidence context
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabis use and acute coronary syndrome. PubMed 30964363
Evidence class is insufficient.
Evidence row 319 / evidence context
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Endocannabinoids, blood pressure and the human heart. PubMed 18426501
Evidence class is insufficient.
Evidence row 320 / evidence context
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. PubMed 37648266
Evidence class is insufficient.
Evidence row 325 / evidence context
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
A new HPLC method with multiple detection systems for impurity analysis and discrimination of natural versus synthetic cannabidiol. PubMed 38940871
Evidence class is insufficient.
Evidence row 326 / evidence context
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Statewide Variation in Cannabinoid Regulations. PubMed 36848540
Evidence class is insufficient.
Evidence row 327 / evidence context
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabis Contaminants Limit Pharmacological Use of Cannabidiol. PubMed 33013414
Evidence class is insufficient.
Evidence row 328 / evidence context
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Pesticides and trace elements in cannabis: Analytical and environmental challenges and opportunities. PubMed 31471034
Evidence class is insufficient.
Evidence row 329 / evidence context
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cautious Hope for Cannabidiol (CBD) in Rheumatology Care. PubMed 32144889
Evidence class is insufficient.
Evidence row 330 / evidence context
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues. PubMed 27683558
Evidence class is insufficient.
Evidence row 331 / evidence context
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Heavy metal and phthalate contamination and labeling integrity in a large sample of US commercially available cannabidiol (CBD) products. PubMed 35987236
Evidence class is insufficient.
Evidence row 332 / evidence context
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabidiol Gummy Products: LC-MS/MS Assessment of Cannabinoid Concentrations. PubMed 40454463
Evidence class is insufficient.
Evidence row 333 / evidence context
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Acid-Catalyzed Conversion of Cannabidiol to Tetrahydrocannabinols: En Route to Demystifying Manufacturing Processes and Controlling the Reaction Outcomes. PubMed 40250991
Evidence class is insufficient.
Evidence row 335 / evidence context
Delta-8 THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Delta-8 tetrahydrocannabinol: a scoping review and commentary. PubMed 36710464
Evidence class is insufficient.
Evidence row 336 / evidence context
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
The potential role of cannabinoids in dermatology. PubMed 31599175
Evidence class is insufficient.
Evidence row 337 / evidence context
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabis and the skin. PubMed 34785006
Evidence class is insufficient.
Evidence row 339 / evidence context
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabinoids and Their Receptors in Skin Diseases. PubMed 38003712
Evidence class is insufficient.
Evidence row 340 / evidence context
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabidiol in Skin Health: A Comprehensive Review of Topical Applications in Dermatology and Cosmetic Science. PubMed 41008526
Evidence class is insufficient.
Evidence row 341 / evidence context
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabis sativa and Skin Health: Dissecting the Role of Phytocannabinoids. PubMed 33851375
Evidence class is insufficient.
Evidence row 342 / evidence context
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Potential of cannabidiol as acne and acne scar treatment: novel insights into molecular pathways of pathophysiological factors. PubMed 38904694
Evidence class is insufficient.
Evidence row 343 / evidence context
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Endocannabinoid system and its modulation of brain, gut, joint and skin inflammation. PubMed 33909195
Evidence class is insufficient.
Evidence row 344 / evidence context
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders. PubMed 30138623
Evidence class is insufficient.
Evidence row 345 / evidence context
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Sebaceous immunobiology - skin homeostasis, pathophysiology, coordination of innate immunity and inflammatory response and disease associations. PubMed 36439142
Evidence class is insufficient.
Evidence row 346 / evidence context
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. PubMed 19608284
Evidence class is insufficient.
Evidence row 348 / evidence context
Delta-8 THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Delta-8, a Cannabis-Derived Tetrahydrocannabinol Isomer: Evaluating Case Report Data in the Food and Drug Administration Adverse Event Reporting System (FAERS) Database. PubMed 36742440
Evidence class is insufficient.
Evidence row 349 / evidence context
Delta-8 THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Delta-8 tetrahydrocannabinol, delta-10 tetrahydrocannabinol, and tetrahydrocannabinol-O acetate exposures reported to America's Poison Centers. PubMed 38686923
Evidence class is insufficient.
Evidence row 352 / evidence context
Delta-8 THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Delta-8 THC Retail Availability, Price, and Minimum Purchase Age. PubMed 36342930
Evidence class is insufficient.
Evidence row 355 / evidence context
HHC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
A Survey Study of Individuals Using Hexahydrocannabinol Cannabis Products: Use Patterns and Perceived Effects. PubMed 37934167
Evidence class is insufficient.
Evidence row 357 / evidence context
THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms.
insufficient / very_low confidence.
An Introduction to the Endogenous Cannabinoid System. PubMed 26698193
Evidence class is insufficient.
Evidence row 358 / evidence context
Cannabinoids modulates TRP channel activity or ionotropic cannabinoid target mechanisms.
insufficient / very_low confidence.
Temperature-sensitive transient receptor potential vanilloid channels: structural insights into ligand-dependent activation. PubMed 33155670
Evidence class is insufficient.
Evidence row 359 / evidence context
THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms.
insufficient / very_low confidence.
The Pharmacological Case for Cannabigerol. PubMed 33168643
Evidence class is insufficient.
Evidence row 361 / evidence context
CBD modulates TRP channel activity or ionotropic cannabinoid target mechanisms.
insufficient / very_low confidence.
Pharmacological effects of cannabidiol by transient receptor potential channels. PubMed 35483477
Evidence class is insufficient.
Evidence row 362 / evidence context
THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms.
insufficient / very_low confidence.
Cannabinoids in the landscape of cancer. PubMed 34259916
Evidence class is insufficient.
Evidence row 363 / evidence context
THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms.
insufficient / very_low confidence.
Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8. PubMed 18354058
Evidence class is insufficient.
Evidence row 371 / evidence context
CBD modulates endocannabinoid enzyme activity or metabolic mechanisms.
insufficient / very_low confidence.
Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. PubMed 36912195
Evidence class is insufficient.
Evidence row 372 / evidence context
CBD modulates endocannabinoid enzyme activity or metabolic mechanisms.
insufficient / very_low confidence.
Metabolism and liver toxicity of cannabidiol. PubMed 38904421
Evidence class is insufficient.
Evidence row 373 / evidence context
CBD modulates endocannabinoid enzyme activity or metabolic mechanisms.
insufficient / very_low confidence.
Clinical guidance for cannabidiol-associated hepatotoxicity: A narrative review. PubMed 39228144
Evidence class is insufficient.
Evidence row 374 / evidence context
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
The Psychiatric Consequences of Cannabinoids. PubMed 29678279
Evidence class is insufficient.
Evidence row 375 / evidence context
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Pharmacotherapies for cannabis dependence. PubMed 30687936
Evidence class is insufficient.
Evidence row 376 / evidence context
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids: A Systematic Review and Meta-analysis. PubMed 32271390
Evidence class is insufficient.
Evidence row 377 / evidence context
THC studied for Cannabinoids and nausea/vomiting research outcomes.
insufficient / very_low confidence.
Regulation of nausea and vomiting by cannabinoids. PubMed 21175589
Evidence class is insufficient.
Evidence row 378 / evidence context
THC studied for Cannabinoids and nausea/vomiting research outcomes.
insufficient / very_low confidence.
Cannabinoids: the lows and the highs of chemotherapy-induced nausea and vomiting. PubMed 30720344
Evidence class is insufficient.
Evidence row 379 / evidence context
THC studied for Cannabinoids and nausea/vomiting research outcomes.
insufficient / very_low confidence.
Cannabinoids As Potential Treatment for Chemotherapy-Induced Nausea and Vomiting. PubMed 27507945
Evidence class is insufficient.
Evidence row 380 / evidence context
CBD studied for Seizure and neurodevelopmental outcomes.
insufficient / very_low confidence.
Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. PubMed 36206805
Evidence class is insufficient.
Evidence row 381 / evidence context
CBD studied for Seizure and neurodevelopmental outcomes.
insufficient / very_low confidence.
Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. PubMed 39007525
Evidence class is insufficient.
Evidence row 383 / evidence context
CBD studied for Seizure and neurodevelopmental outcomes.
insufficient / very_low confidence.
Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome. PubMed 33754312
Evidence class is insufficient.
Evidence row 384 / evidence context
CBD studied for Seizure and neurodevelopmental outcomes.
insufficient / very_low confidence.
Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders. PubMed 33332006
Evidence class is insufficient.
Evidence row 385 / evidence context
CBD studied for Seizure and neurodevelopmental outcomes.
insufficient / very_low confidence.
Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. PubMed 36417631
Evidence class is insufficient.
Evidence row 386 / evidence context
CBD studied for Seizure and neurodevelopmental outcomes.
insufficient / very_low confidence.
Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies. PubMed 36194365
Evidence class is insufficient.
Evidence row 390 / evidence context
CBD studied for Seizure and neurodevelopmental outcomes.
insufficient / very_low confidence.
CBD in the Treatment of Epilepsy. PubMed 38731471
Evidence class is insufficient.
Evidence row 391 / evidence context
CBD studied for Seizure and neurodevelopmental outcomes.
insufficient / very_low confidence.
Pharmacological diversity amongst approved and emerging antiseizure medications for the treatment of developmental and epileptic encephalopathies. PubMed 37655228
Evidence class is insufficient.
Evidence row 392 / evidence context
CBD studied for Pain-related outcomes.
insufficient / very_low confidence.
Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. PubMed 35510826
Evidence class is insufficient.
Evidence row 393 / evidence context
CBD studied for Pain-related outcomes.
insufficient / very_low confidence.
Cannabis-based medicines for chronic neuropathic pain in adults. PubMed 29513392
Evidence class is insufficient.
Evidence row 394 / evidence context
CBD studied for Pain-related outcomes.
insufficient / very_low confidence.
Cannabis-Based Products for Chronic Pain : An Updated Systematic Review. PubMed 41429020
Evidence class is insufficient.
Evidence row 397 / evidence context
CBD studied for Pain-related outcomes.
insufficient / very_low confidence.
Nabiximols in Chronic Neuropathic Pain: A Meta-Analysis of Randomized Placebo-Controlled Trials. PubMed 33561282
Evidence class is insufficient.
Evidence row 399 / evidence context
CBD studied for Pain-related outcomes.
insufficient / very_low confidence.
Cannabinoids: Medical implications. PubMed 26912385
Evidence class is insufficient.
Evidence row 400 / evidence context
CBD studied for Pain-related outcomes.
insufficient / very_low confidence.
Cannabinoids as a Natural Alternative for the Management of Neuropathic Pain: A Systematic Review of Randomized Placebo-Controlled Trials. PubMed 39445260
Evidence class is insufficient.
Evidence row 408 / evidence context
CBD studied for Sleep.
insufficient / very_low confidence.
The Effects of Cannabinoids on Sleep. PubMed 35459406
Evidence class is insufficient.
Evidence row 410 / evidence context
CBD studied for Sleep.
insufficient / very_low confidence.
Effectiveness of cannabinoids on subjective sleep quality in people with and without insomnia or poor sleep: A systematic review and meta-analysis of randomised studies. PubMed 40929927
Evidence class is insufficient.
Evidence row 411 / evidence context
CBD studied for Sleep.
insufficient / very_low confidence.
The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis. PubMed 41856154
Evidence class is insufficient.
Evidence row 412 / evidence context
CBD studied for Sleep.
insufficient / very_low confidence.
Should Oncologists Recommend Cannabis? PubMed 31161270
Evidence class is insufficient.
Evidence row 413 / evidence context
CBD studied for Sleep.
insufficient / very_low confidence.
Cannabis dosing and administration for sleep: a systematic review. PubMed 36107800
Evidence class is insufficient.
Evidence row 415 / evidence context
CBD studied for Seizure and neurodevelopmental outcomes.
insufficient / very_low confidence.
Antiseizure medications for Lennox-Gastaut Syndrome: Comprehensive review and proposed consensus treatment algorithm. PubMed 39854828
Evidence class is insufficient.
Evidence row 418 / evidence context
CBD studied for Seizure and neurodevelopmental outcomes.
insufficient / very_low confidence.
Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis. PubMed 38427284
Evidence class is insufficient.
Evidence row 421 / evidence context
CBD studied for Seizure and neurodevelopmental outcomes.
insufficient / very_low confidence.
State-of-the-art management of Dravet syndrome. PubMed 40836583
Evidence class is insufficient.
Evidence row 423 / evidence context
CBD studied for Seizure and neurodevelopmental outcomes.
insufficient / very_low confidence.
Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. PubMed 37695433
Evidence class is insufficient.
Evidence row 424 / evidence context
CBD studied for Seizure and neurodevelopmental outcomes.
insufficient / very_low confidence.
Long-term safety and effectiveness of fenfluramine in children and adults with Dravet syndrome. PubMed 40072476
Evidence class is insufficient.
Evidence row 425 / evidence context
CBD studied for Seizure and neurodevelopmental outcomes.
insufficient / very_low confidence.
Treatment of Dravet Syndrome. PubMed 27264138
Evidence class is insufficient.
Evidence row 426 / evidence context
CBD studied for Seizure and neurodevelopmental outcomes.
insufficient / very_low confidence.
Current and emerging pharmacotherapies in Lennox-Gastaut syndrome. PubMed 40468679
Evidence class is insufficient.
Evidence row 427 / evidence context
CBD studied for Seizure and neurodevelopmental outcomes.
insufficient / very_low confidence.
Anti-seizure medications for Lennox-Gastaut syndrome. PubMed 33825230
Evidence class is insufficient.
Evidence row 428 / evidence context
CBD studied for Seizure and neurodevelopmental outcomes.
insufficient / very_low confidence.
Lennox-Gastaut syndrome: New treatments and treatments under investigation. PubMed 32409177
Evidence class is insufficient.
Evidence row 429 / evidence context
CBD studied for Seizure and neurodevelopmental outcomes.
insufficient / very_low confidence.
Management of Lennox-Gastaut syndrome beyond childhood: A comprehensive review. PubMed 33243685
Evidence class is insufficient.
Evidence row 430 / evidence context
CBD studied for Pain-related outcomes.
insufficient / very_low confidence.
Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. PubMed 37648266
Evidence class is insufficient.
Evidence row 434 / evidence context
THC studied for Psychiatric risk.
insufficient / very_low confidence.
Therapeutic Use of Cannabis and Cannabinoids: A Review. PubMed 41296368
Evidence class is insufficient.
Evidence row 435 / evidence context
THC studied for Psychiatric risk.
insufficient / very_low confidence.
Therapeutic potential of minor cannabinoids in psychiatric disorders: A systematic review. PubMed 39541799
Evidence class is insufficient.
Evidence row 436 / evidence context
THC studied for Psychiatric risk.
insufficient / very_low confidence.
Cannabis Use and the Risk for Psychosis and Affective Disorders. PubMed 31647377
Evidence class is insufficient.
Evidence row 437 / evidence context
THC studied for Psychiatric risk.
insufficient / very_low confidence.
Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits. PubMed 39299947
Evidence class is insufficient.
Evidence row 438 / evidence context
THC studied for Psychiatric risk.
insufficient / very_low confidence.
Cannabis and Mental Health: A Review. PubMed 41801216
Evidence class is insufficient.
Evidence row 439 / evidence context
THC studied for Psychiatric risk.
insufficient / very_low confidence.
Association of cannabis potency with mental ill health and addiction: a systematic review. PubMed 35901795
Evidence class is insufficient.
Evidence row 440 / evidence context
THC studied for Psychiatric risk.
insufficient / very_low confidence.
Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders. PubMed 33228239
Evidence class is insufficient.
Evidence row 441 / evidence context
THC studied for Psychiatric risk.
insufficient / very_low confidence.
High-Concentration Delta-9-Tetrahydrocannabinol Cannabis Products and Mental Health Outcomes : A Systematic Review. PubMed 40854216
Evidence class is insufficient.
Evidence row 442 / evidence context
THC studied for Psychiatric risk.
insufficient / very_low confidence.
Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. PubMed 31672337
Evidence class is insufficient.
Evidence row 443 / evidence context
THC studied for Cardiovascular risk.
insufficient / very_low confidence.
Cardiovascular consequences of marijuana use. PubMed 12412838
Evidence class is insufficient.
Evidence row 444 / evidence context
THC studied for Cardiovascular risk.
insufficient / very_low confidence.
Acute Effects of Cannabis Inhalation on Arterial Stiffness, Vascular Endothelial Function, and Cardiac Function. PubMed 39575727
Evidence class is insufficient.
Evidence row 445 / evidence context
THC studied for Cardiovascular risk.
insufficient / very_low confidence.
Cardiovascular system effects of marijuana. PubMed 12412837
Evidence class is insufficient.
Evidence row 446 / evidence context
THC studied for Cardiovascular risk.
insufficient / very_low confidence.
Cannabinoids and the heart-a psychiatrist's perspective. PubMed 39331072
Evidence class is insufficient.
Evidence row 447 / evidence context
THC studied for Cardiovascular risk.
insufficient / very_low confidence.
The acute cardiovascular response to dynamic exercise and recovery following cannabis use. PubMed 41115058
Evidence class is insufficient.
Evidence row 448 / evidence context
THC studied for Cardiovascular risk.
insufficient / very_low confidence.
At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction. PubMed 22503477
Evidence class is insufficient.
Evidence row 449 / evidence context
THC studied for Cardiovascular risk.
insufficient / very_low confidence.
A Systematic Review and Meta-Analysis of the In Vivo Haemodynamic Effects of Δ⁸-Tetrahydrocannabinol. PubMed 29385080
Evidence class is insufficient.
Evidence row 452 / evidence context
THC studied for Dependence and withdrawal.
insufficient / very_low confidence.
Pharmacotherapies for cannabis use disorder. PubMed 41025421
Evidence class is insufficient.
Evidence row 453 / evidence context
THC studied for Dependence and withdrawal.
insufficient / very_low confidence.
Clinical management of cannabis withdrawal. PubMed 34791767
Evidence class is insufficient.
Evidence row 454 / evidence context
THC studied for Dependence and withdrawal.
insufficient / very_low confidence.
Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. PubMed 35510826
Evidence class is insufficient.
Evidence row 455 / evidence context
THC studied for Dependence and withdrawal.
insufficient / very_low confidence.
The differential effects of medicinal cannabis on mental health: A systematic review. PubMed 40186931
Evidence class is insufficient.
Evidence row 456 / evidence context
THC studied for Dependence and withdrawal.
insufficient / very_low confidence.
Pharmacotherapies for cannabis dependence. PubMed 30687936
Evidence class is insufficient.
Evidence row 457 / evidence context
THC studied for Dependence and withdrawal.
insufficient / very_low confidence.
Actions of delta-9-tetrahydrocannabinol in cannabis: relation to use, abuse, dependence. PubMed 19367504
Evidence class is insufficient.
Evidence row 458 / evidence context
THC studied for Dependence and withdrawal.
insufficient / very_low confidence.
[Cannabis use and cannabis use disorders]. PubMed 39134752
Evidence class is insufficient.
Evidence row 459 / evidence context
THC studied for Dependence and withdrawal.
insufficient / very_low confidence.
Pharmacotherapies for cannabis dependence. PubMed 25515775
Evidence class is insufficient.
Evidence row 460 / evidence context
THC studied for Dependence and withdrawal.
insufficient / very_low confidence.
Alleviation of opioid withdrawal by cannabis and delta-9-tetrahydrocannabinol: A systematic review of observational and experimental human studies. PubMed 36434879
Evidence class is insufficient.
Evidence row 461 / evidence context
THC studied for Cognition and memory.
insufficient / very_low confidence.
Cannabinoids: Medical implications. PubMed 26912385
Evidence class is insufficient.
Evidence row 463 / evidence context
THC studied for Cognition and memory.
insufficient / very_low confidence.
Developing a phone-based measure of impairment after acute oral ∆9-tetrahydrocannabinol. PubMed 31407943
Evidence class is insufficient.
Evidence row 464 / evidence context
THC studied for Cognition and memory.
insufficient / very_low confidence.
Acute effects of naturalistic THC vs. CBD use on recognition memory: a preliminary study. PubMed 33526107
Evidence class is insufficient.
Evidence row 466 / evidence context
THC studied for Cognition and memory.
insufficient / very_low confidence.
Effects of different methods of cannabis use on cognition and blood THC: A systematic review. PubMed 40368229
Evidence class is insufficient.
Evidence row 467 / evidence context
THC studied for Cognition and memory.
insufficient / very_low confidence.
[Cannabis: Similarities and differences with tobacco]. PubMed 32381378
Evidence class is insufficient.
Evidence row 470 / evidence context
THC studied for Cognition and memory.
insufficient / very_low confidence.
The acute effects of cannabis on human executive function. PubMed 30199388
Evidence class is insufficient.
Evidence row 471 / evidence context
THC studied for Pain-related outcomes.
insufficient / very_low confidence.
Therapeutic Use of Cannabis and Cannabinoids: A Review. PubMed 41296368
Evidence class is insufficient.
Evidence row 472 / evidence context
THC studied for Pain-related outcomes.
insufficient / very_low confidence.
Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. PubMed 35982439
Evidence class is insufficient.
Evidence row 473 / evidence context
THC studied for Pain-related outcomes.
insufficient / very_low confidence.
Cannabis-Based Products for Chronic Pain : An Updated Systematic Review. PubMed 41429020
Evidence class is insufficient.
Evidence row 475 / evidence context
THC studied for Pain-related outcomes.
insufficient / very_low confidence.
Pharmacology of Medical Cannabis. PubMed 31332738
Evidence class is insufficient.
Evidence row 476 / evidence context
THC studied for Pain-related outcomes.
insufficient / very_low confidence.
Cannabis-based medicines and medical cannabis for adults with cancer pain. PubMed 37283486
Evidence class is insufficient.
Evidence row 477 / evidence context
THC studied for Pain-related outcomes.
insufficient / very_low confidence.
Cannabis-Based Products for Chronic Pain : A Systematic Review. PubMed 35667066
Evidence class is insufficient.
Evidence row 478 / evidence context
THC studied for Pain-related outcomes.
insufficient / very_low confidence.
Practical considerations in medical cannabis administration and dosing. PubMed 29307505
Evidence class is insufficient.
Evidence row 479 / evidence context
THC studied for Pain-related outcomes.
insufficient / very_low confidence.
Cannabis-Based Medicines and Medical Cannabis for Chronic Neuropathic Pain. PubMed 34802112
Evidence class is insufficient.
Evidence row 480 / evidence context
THC studied for Nausea and vomiting.
insufficient / very_low confidence.
Therapeutic Use of Cannabis and Cannabinoids: A Review. PubMed 41296368
Evidence class is insufficient.
Evidence row 481 / evidence context
THC studied for Nausea and vomiting.
insufficient / very_low confidence.
Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. PubMed 35982439
Evidence class is insufficient.
Evidence row 483 / evidence context
THC studied for Nausea and vomiting.
insufficient / very_low confidence.
Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits. PubMed 39299947
Evidence class is insufficient.
Evidence row 484 / evidence context
THC studied for Nausea and vomiting.
insufficient / very_low confidence.
Cannabinoids: Therapeutic Use in Clinical Practice. PubMed 35328765
Evidence class is insufficient.
Evidence row 485 / evidence context
THC studied for Nausea and vomiting.
insufficient / very_low confidence.
Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to antiemetics. PubMed 27274310
Evidence class is insufficient.
Evidence row 486 / evidence context
THC studied for Nausea and vomiting.
insufficient / very_low confidence.
The Risk of QTc Prolongation with Antiemetics in the Palliative Care Setting: A Narrative Review. PubMed 33974499
Evidence class is insufficient.
Evidence row 487 / evidence context
THC studied for Nausea and vomiting.
insufficient / very_low confidence.
Chemotherapy-induced nausea and vomiting. PubMed 18391612
Evidence class is insufficient.
Evidence row 488 / evidence context
THC studied for Appetite and metabolic outcomes.
insufficient / very_low confidence.
[Dronabinol (delta9-tetrahydrocannabinol) in long-term treatment. Symptom control in patients with multiple sclerosis and spasticity, neuropathic pain, loss of appetite and cachexia]. PubMed 23570087
Evidence class is insufficient.
Evidence row 489 / evidence context
THC studied for Appetite and metabolic outcomes.
insufficient / very_low confidence.
Cancer cachexia and cannabinoids. PubMed 10575285
Evidence class is insufficient.
Evidence row 490 / evidence context
THC studied for Appetite and metabolic outcomes.
insufficient / very_low confidence.
Orexigenic and anabolic agents. PubMed 12608509
Evidence class is insufficient.
Evidence row 491 / evidence context
THC studied for Appetite and metabolic outcomes.
insufficient / very_low confidence.
Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer. PubMed 29670357
Evidence class is insufficient.
Evidence row 493 / evidence context
THC studied for Appetite and metabolic outcomes.
insufficient / very_low confidence.
Systematic review and meta-analysis of cannabinoids in palliative medicine. PubMed 29400010
Evidence class is insufficient.
Evidence row 494 / evidence context
THC studied for Appetite and metabolic outcomes.
insufficient / very_low confidence.
Clinical utility of dronabinol in the treatment of weight loss associated with HIV and AIDS. PubMed 26929669
Evidence class is insufficient.
Evidence row 495 / evidence context
THC studied for Appetite and metabolic outcomes.
insufficient / very_low confidence.
Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. PubMed 15050664
Evidence class is insufficient.
Evidence row 496 / evidence context
THC studied for Appetite and metabolic outcomes.
insufficient / very_low confidence.
The cancer cachexia syndrome. PubMed 9208884
Evidence class is insufficient.
Evidence row 498 / evidence context
THC studied for Sleep.
insufficient / very_low confidence.
The differential effects of medicinal cannabis on mental health: A systematic review. PubMed 40186931
Evidence class is insufficient.
Evidence row 501 / evidence context
THC studied for Sleep.
insufficient / very_low confidence.
Should Oncologists Recommend Cannabis? PubMed 31161270
Evidence class is insufficient.
Evidence row 502 / evidence context
THC studied for Sleep.
insufficient / very_low confidence.
Cannabis dosing and administration for sleep: a systematic review. PubMed 36107800
Evidence class is insufficient.
Evidence row 504 / evidence context
THC studied for Sleep.
insufficient / very_low confidence.
Cannabinoids in the Treatment of Insomnia Disorder: A Systematic Review and Meta-Analysis. PubMed 33244728
Evidence class is insufficient.
Evidence row 506 / evidence context
THC studied for Sleep.
insufficient / very_low confidence.
Use of Cannabidiol in the Management of Insomnia: A Systematic Review. PubMed 36149724
Evidence class is insufficient.
Evidence row 507 / evidence context
THC studied for Sleep.
insufficient / very_low confidence.
Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies. PubMed 32603954
Evidence class is insufficient.
Evidence row 513 / evidence context
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Examining the hepatotoxic potential of cannabidiol, cannabidiol-containing hemp extract, and cannabinol at consumer-relevant exposure concentrations in primary human hepatocytes. PubMed 38924151
Evidence class is insufficient.
Evidence row 514 / evidence context
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
[Cannabis: Effects in the Central Nervous System. Therapeutic, societal and legal consequences]. PubMed 27428345
Evidence class is insufficient.
Evidence row 515 / evidence context
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Review of NIOSH Cannabis-Related Health Hazard Evaluations and Research. PubMed 32053725
Evidence class is insufficient.
Evidence row 516 / evidence context
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Evaluation of the anti-inflammatory effects of selected cannabinoids and terpenes from Cannabis Sativa employing human primary leukocytes. PubMed 36228902
Evidence class is insufficient.
Evidence row 517 / evidence context
CBN modulates receptor, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms. PubMed 40967679
Evidence class is insufficient.
Evidence row 519 / evidence context
CBN modulates receptor, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
Pharmacological actions of cannabinoids. PubMed 16596770
Evidence class is insufficient.
Evidence row 520 / evidence context
CBN modulates receptor, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
Molecular Pharmacology of Phytocannabinoids. PubMed 28120231
Evidence class is insufficient.
Evidence row 521 / evidence context
CBN modulates receptor, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
The peripheral cannabinoid receptor, Cb2, in retrovirally-induced leukemic transformation and normal hematopoiesis. PubMed 10036999
Evidence class is insufficient.
Evidence row 523 / evidence context
CBN modulates receptor, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
Phytocannabinoids: Exploring Pharmacological Profiles and Their Impact on Therapeutical Use. PubMed 38673788
Evidence class is insufficient.
Evidence row 529 / evidence context
CBN studied for Skin and inflammatory dermatology.
insufficient / very_low confidence.
Phytocannabinoids: Exploring Pharmacological Profiles and Their Impact on Therapeutical Use. PubMed 38673788
Evidence class is insufficient.
Evidence row 530 / evidence context
CBN studied for Skin and inflammatory dermatology.
insufficient / very_low confidence.
Cannabinoids, inflammation, and fibrosis. PubMed 27435265
Evidence class is insufficient.
Evidence row 535 / evidence context
CBN studied for Pain-related outcomes.
insufficient / very_low confidence.
Cannabinoid receptor 2 (Cb2r) mediates cannabinol (CBN) induced developmental defects in zebrafish. PubMed 36424484
Evidence class is insufficient.
Evidence row 536 / evidence context
CBN studied for Pain-related outcomes.
insufficient / very_low confidence.
Cannabinoids, inflammation, and fibrosis. PubMed 27435265
Evidence class is insufficient.
Evidence row 537 / evidence context
CBN studied for Pain-related outcomes.
insufficient / very_low confidence.
[Marijuana--2000]. PubMed 11367861
Evidence class is insufficient.
Evidence row 539 / evidence context
CBN studied for Pain-related outcomes.
insufficient / very_low confidence.
Cannabis: Chemistry, extraction and therapeutic applications. PubMed 34838836
Evidence class is insufficient.
Evidence row 541 / evidence context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential. PubMed 39598860
Evidence class is insufficient.
Evidence row 543 / evidence context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabinoids in clinical practice. PubMed 11152013
Evidence class is insufficient.
Evidence row 545 / evidence context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Comprehensive mini-review: therapeutic potential of cannabigerol - focus on the cardiovascular system. PubMed 40206058
Evidence class is insufficient.
Evidence row 549 / evidence context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabigerol Mitigates Haloperidol-Induced Vacuous Chewing Movements in Mice. PubMed 39699828
Evidence class is insufficient.
Evidence row 551 / evidence context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Non-psychotropic cannabinoids as inhibitors of TET1 protein. PubMed 35462234
Evidence class is insufficient.
Evidence row 552 / evidence context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabigerol and Cannabinoid Receptors in Major Depressive Disorder: Network Pharmacology, Molecular Docking, and In-vivo Analysis. PubMed 40326034
Evidence class is insufficient.
Evidence row 553 / evidence context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma. PubMed 33562819
Evidence class is insufficient.
Evidence row 555 / evidence context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Under the umbrella of depression and Alzheimer's disease physiopathology: Can cannabinoids be a dual-pleiotropic therapy? PubMed 37414155
Evidence class is insufficient.
Evidence row 557 / evidence context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
The Cytotoxic Effects of Cannabidiol and Cannabigerol on Glioblastoma Stem Cells May Mostly Involve GPR55 and TRPV1 Signalling. PubMed 36497400
Evidence class is insufficient.
Evidence row 558 / evidence context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects. PubMed 42352060
Evidence class is insufficient.
Evidence row 559 / evidence context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Identifying and Quantifying Cannabinoids in Biological Matrices in the Medical and Legal Cannabis Era. PubMed 32628766
Evidence class is insufficient.
Evidence row 563 / evidence context
CBG modulates receptor, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential. PubMed 39598860
Evidence class is insufficient.
Evidence row 564 / evidence context
CBG modulates receptor, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. PubMed 21749363
Evidence class is insufficient.
Evidence row 565 / evidence context
CBG modulates receptor, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
The Effects of Cannabinoids on Pro- and Anti-Inflammatory Cytokines: A Systematic Review of In Vivo Studies. PubMed 33998900
Evidence class is insufficient.
Evidence row 566 / evidence context
CBG modulates receptor, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
Cannabigerol and Cannabicyclol Block SARS-CoV-2 Cell Fusion. PubMed 38885660
Evidence class is insufficient.
Evidence row 567 / evidence context
CBG modulates receptor, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
The Pharmacological Case for Cannabigerol. PubMed 33168643
Evidence class is insufficient.
Evidence row 568 / evidence context
CBG modulates receptor, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms. PubMed 40967679
Evidence class is insufficient.
Evidence row 569 / evidence context
CBG modulates receptor, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
Molecular Pharmacology of Phytocannabinoids. PubMed 28120231
Evidence class is insufficient.
Evidence row 571 / evidence context
CBG modulates receptor, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
Cannabinoids in autoimmune diseases: mechanistic insights and translational challenges. PubMed 42105814
Evidence class is insufficient.
Evidence row 574 / evidence context
CBG modulates receptor, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial. PubMed 39003387
Evidence class is insufficient.
Evidence row 575 / evidence context
CBG modulates receptor, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
The Origin and Biomedical Relevance of Cannabigerol. PubMed 35887277
Evidence class is insufficient.
Evidence row 576 / evidence context
CBG modulates receptor, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
Cannabinoid hyperemesis syndrome. PubMed 22150623
Evidence class is insufficient.
Evidence row 577 / evidence context
CBG modulates receptor, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
The Pharmacology of Cannabinoids in Chronic Pain. PubMed 40046175
Evidence class is insufficient.
Evidence row 582 / evidence context
CBG modulates receptor, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
Acute Cannabigerol Administration Lowers Blood Pressure in Mice. PubMed 35615681
Evidence class is insufficient.
Evidence row 584 / evidence context
CBG studied for Inflammation-related outcomes.
insufficient / very_low confidence.
Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential. PubMed 39598860
Evidence class is insufficient.
Evidence row 585 / evidence context
CBG studied for Inflammation-related outcomes.
insufficient / very_low confidence.
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. PubMed 21749363
Evidence class is insufficient.
Evidence row 587 / evidence context
CBG studied for Inflammation-related outcomes.
insufficient / very_low confidence.
The Effects of Cannabinoids on Pro- and Anti-Inflammatory Cytokines: A Systematic Review of In Vivo Studies. PubMed 33998900
Evidence class is insufficient.
Evidence row 593 / evidence context
CBG studied for Inflammation-related outcomes.
insufficient / very_low confidence.
Medical Cannabis Activity Against Inflammation: Active Compounds and Modes of Action. PubMed 35614947
Evidence class is insufficient.
Evidence row 600 / evidence context
CBG studied for Inflammation-related outcomes.
insufficient / very_low confidence.
Cannabigerol and cannabichromene in Cannabis sativa L. PubMed 36654096
Evidence class is insufficient.
Evidence row 601 / evidence context
CBG studied for Inflammation-related outcomes.
insufficient / very_low confidence.
The Use of Cannabinoids in Colitis: A Systematic Review and Meta-Analysis. PubMed 29562280
Evidence class is insufficient.
Evidence row 604 / evidence context
CBG studied for Inflammation-related outcomes.
insufficient / very_low confidence.
Development of a Rapid LC-MS/MS Method for the Quantification of Cannabidiol, Cannabidivarin, Δ9-Tetrahydrocannabivarin, and Cannabigerol in Mouse Peripheral Tissues. PubMed 28343385
Evidence class is insufficient.
Evidence row 609 / evidence context
CBG studied for Skin and inflammatory dermatology.
insufficient / very_low confidence.
Cannabidiol and Cannabigerol Exert Antimicrobial Activity without Compromising Skin Microbiota. PubMed 36768709
Evidence class is insufficient.
Evidence row 615 / evidence context
CBG studied for Skin and inflammatory dermatology.
insufficient / very_low confidence.
Minor Cannabinoids as Inhibitors of Skin Inflammation: Chemical Synthesis and Biological Evaluation. PubMed 38889235
Evidence class is insufficient.
Evidence row 618 / evidence context
CBG studied for Skin and inflammatory dermatology.
insufficient / very_low confidence.
Design, synthesis, and biological profiling of fluorinated cannabidiol and cannabigerol derivatives as promising therapeutic agents. PubMed 41645347
Evidence class is insufficient.
Evidence row 620 / evidence context
CBG studied for Appetite and metabolic outcomes.
insufficient / very_low confidence.
It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets. PubMed 32899626
Evidence class is insufficient.
Evidence row 622 / evidence context
CBG studied for Appetite and metabolic outcomes.
insufficient / very_low confidence.
Cannabinoids in autoimmune diseases: mechanistic insights and translational challenges. PubMed 42105814
Evidence class is insufficient.
Evidence row 625 / evidence context
CBG studied for Appetite and metabolic outcomes.
insufficient / very_low confidence.
Cannabigerol and cannabichromene in Cannabis sativa L. PubMed 36654096
Evidence class is insufficient.
Evidence row 627 / evidence context
CBG studied for Appetite and metabolic outcomes.
insufficient / very_low confidence.
Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives. PubMed 36397993
Evidence class is insufficient.
Evidence row 633 / evidence context
CBG studied for Appetite and metabolic outcomes.
insufficient / very_low confidence.
Phytocannabinoids as novel therapeutic agents in CNS disorders. PubMed 21924288
Evidence class is insufficient.
Evidence row 638 / evidence context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
The Potential of Cannabichromene (CBC) as a Therapeutic Agent. PubMed 38777605
Evidence class is insufficient.
Evidence row 639 / evidence context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management. PubMed 40872492
Evidence class is insufficient.
Evidence row 640 / evidence context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review. PubMed 37630401
Evidence class is insufficient.
Evidence row 642 / evidence context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
A systematic review of analytical methodologies capable of analysing phytocannabinoids in cosmetics. PubMed 38229238
Evidence class is insufficient.
Evidence row 645 / evidence context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
CBD, a precursor of THC in e-cigarettes. PubMed 33903673
Evidence class is insufficient.
Evidence row 647 / evidence context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Under the umbrella of depression and Alzheimer's disease physiopathology: Can cannabinoids be a dual-pleiotropic therapy? PubMed 37414155
Evidence class is insufficient.
Evidence row 648 / evidence context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects. PubMed 42352060
Evidence class is insufficient.
Evidence row 649 / evidence context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Identifying and Quantifying Cannabinoids in Biological Matrices in the Medical and Legal Cannabis Era. PubMed 32628766
Evidence class is insufficient.
Evidence row 650 / evidence context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabis Vaping: Existing and Emerging Modalities, Chemistry, and Pulmonary Toxicology. PubMed 34622654
Evidence class is insufficient.
Evidence row 652 / evidence context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Pre-puberty cannabichromene exposure modulates reproductive function via alteration of spermatogenesis, steroidogenesis, and eNOS pathway metabolites. PubMed 37396845
Evidence class is insufficient.
Evidence row 653 / evidence context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Genotoxicity of selected cannabinoids in human lymphoblastoid TK6 cells. PubMed 39172143
Evidence class is insufficient.
Evidence row 656 / evidence context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Development and validation of a fit-for-purpose UHPLC-ESI-MS/MS method for the quantitation of cannabinoids in different matrices. PubMed 36854205
Evidence class is insufficient.
Evidence row 657 / evidence context
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. PubMed 21749363
Evidence class is insufficient.
Evidence row 658 / evidence context
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages. PubMed 37764262
Evidence class is insufficient.
Evidence row 659 / evidence context
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
The Potential of Cannabichromene (CBC) as a Therapeutic Agent. PubMed 38777605
Evidence class is insufficient.
Evidence row 660 / evidence context
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management. PubMed 40872492
Evidence class is insufficient.
Evidence row 661 / evidence context
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
Pharmacokinetics of Non-Psychotropic Phytocannabinoids. PubMed 40006604
Evidence class is insufficient.
Evidence row 663 / evidence context
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms. PubMed 40967679
Evidence class is insufficient.
Evidence row 664 / evidence context
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
Molecular Pharmacology of Phytocannabinoids. PubMed 28120231
Evidence class is insufficient.
Evidence row 665 / evidence context
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
Cannabinoids, inflammation, and fibrosis. PubMed 27435265
Evidence class is insufficient.
Evidence row 666 / evidence context
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
Cannabis: Chemistry, extraction and therapeutic applications. PubMed 34838836
Evidence class is insufficient.
Evidence row 667 / evidence context
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
The Pharmacology of Cannabinoids in Chronic Pain. PubMed 40046175
Evidence class is insufficient.
Evidence row 669 / evidence context
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
Cannabigerol and cannabichromene in Cannabis sativa L. PubMed 36654096
Evidence class is insufficient.
Evidence row 670 / evidence context
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
Cannabichromene as a Novel Inhibitor of Th2 Cytokine and JAK/STAT Pathway Activation in Atopic Dermatitis Models. PubMed 39769302
Evidence class is insufficient.
Evidence row 672 / evidence context
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
Effect of Quantitative Structural Properties and Drug Formulation in Four Cannabinoids (Cannabidiol, Cannabigerol, Cannabichromene, and Cannabinol) on Their Lymphatic Transport after Enteral Administration in Rats. PubMed 40611782
Evidence class is insufficient.
Evidence row 673 / evidence context
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
Cannabichromene, Related Phytocannabinoids, and 5-Fluoro-cannabichromene Have Anticonvulsant Properties in a Mouse Model of Dravet Syndrome. PubMed 33395525
Evidence class is insufficient.
Evidence row 677 / evidence context
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
Natural Cannabichromene (CBC) Shows Distinct Scalemicity Grades and Enantiomeric Dominance in Cannabis sativa Strains. PubMed 37023389
Evidence class is insufficient.
Evidence row 681 / evidence context
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
Selected phytocannabinoids inhibit SN-38- and cytokine-evoked increases in epithelial permeability and improve intestinal barrier function in vitro. PubMed 38950639
Evidence class is insufficient.
Evidence row 683 / evidence context
CBC studied for Pain-related outcomes.
insufficient / very_low confidence.
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. PubMed 21749363
Evidence class is insufficient.
Evidence row 686 / evidence context
CBC studied for Pain-related outcomes.
insufficient / very_low confidence.
It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets. PubMed 32899626
Evidence class is insufficient.
Evidence row 694 / evidence context
CBC studied for Pain-related outcomes.
insufficient / very_low confidence.
The Pharmacology of Cannabinoids in Chronic Pain. PubMed 40046175
Evidence class is insufficient.
Evidence row 701 / evidence context
CBC studied for Skin and inflammatory dermatology.
insufficient / very_low confidence.
The Potential of Cannabichromene (CBC) as a Therapeutic Agent. PubMed 38777605
Evidence class is insufficient.
Evidence row 702 / evidence context
CBC studied for Skin and inflammatory dermatology.
insufficient / very_low confidence.
Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review. PubMed 37630401
Evidence class is insufficient.
Evidence row 705 / evidence context
CBC studied for Skin and inflammatory dermatology.
insufficient / very_low confidence.
Cannabigerol and Cannabicyclol Block SARS-CoV-2 Cell Fusion. PubMed 38885660
Evidence class is insufficient.
Evidence row 706 / evidence context
CBC studied for Skin and inflammatory dermatology.
insufficient / very_low confidence.
Minor Cannabinoids as Inhibitors of Skin Inflammation: Chemical Synthesis and Biological Evaluation. PubMed 38889235
Evidence class is insufficient.
Evidence row 709 / evidence context
CBC studied for Skin and inflammatory dermatology.
insufficient / very_low confidence.
Cannabis-Based Phytocannabinoids: Overview, Mechanism of Action, Therapeutic Application, Production, and Affecting Environmental Factors. PubMed 39457041
Evidence class is insufficient.
Evidence row 710 / evidence context
CBC studied for Skin and inflammatory dermatology.
insufficient / very_low confidence.
Cannabinoids as Antibacterial Agents: A Systematic and Critical Review of In Vitro Efficacy Against Streptococcus and Staphylococcus. PubMed 39596719
Evidence class is insufficient.
Evidence row 714 / evidence context
CBC studied for Skin and inflammatory dermatology.
insufficient / very_low confidence.
Geotemporospatial and causal inferential epidemiological overview and survey of USA cannabis, cannabidiol and cannabinoid genotoxicity expressed in cancer incidence 2003-2017: part 1 - continuous bivariate analysis. PubMed 35354487
Evidence class is insufficient.
Evidence row 715 / evidence context
CBC studied for Skin and inflammatory dermatology.
insufficient / very_low confidence.
Design and synthesis of amphiphilic cannabichromene derivatives with antimicrobial potential. PubMed 41202683
Evidence class is insufficient.
Evidence row 716 / evidence context
CBC studied for Skin and inflammatory dermatology.
insufficient / very_low confidence.
Targeting the antioxidant, antimicrobial and anti-inflammatory activity of non-psychotropic Cannabis sativa L.: a comparison with chemotype V. PubMed 41121423
Evidence class is insufficient.
Evidence row 718 / evidence context
CBC studied for Skin and inflammatory dermatology.
insufficient / very_low confidence.
Synthetic Pathways to Non-Psychotropic Phytocannabinoids as Promising Molecules to Develop Novel Antibiotics: A Review. PubMed 37514074
Evidence class is insufficient.
Evidence row 719 / evidence context
CBC studied for Skin and inflammatory dermatology.
insufficient / very_low confidence.
Spent Material Extractives from Hemp Hydrodistillation as an Underexplored Source of Antimicrobial Cannabinoids. PubMed 38927152
Evidence class is insufficient.
Evidence row 722 / evidence context
CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes.
insufficient / very_low confidence.
Enhancing Cannabichromenic Acid Biosynthesis in Saccharomyces cerevisiae. PubMed 39808700
Evidence class is insufficient.
Evidence row 723 / evidence context
CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes.
insufficient / very_low confidence.
In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters. PubMed 35306000
Evidence class is insufficient.
Evidence row 724 / evidence context
CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes.
insufficient / very_low confidence.
Under the umbrella of depression and Alzheimer's disease physiopathology: Can cannabinoids be a dual-pleiotropic therapy? PubMed 37414155
Evidence class is insufficient.
Evidence row 726 / evidence context
CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes.
insufficient / very_low confidence.
Cannabigerol and cannabichromene in Cannabis sativa L. PubMed 36654096
Evidence class is insufficient.
Evidence row 729 / evidence context
CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes.
insufficient / very_low confidence.
Antidepressant Effects of South African Plants: An Appraisal of Ethnobotanical Surveys, Ethnopharmacological and Phytochemical Studies. PubMed 35846999
Evidence class is insufficient.
Evidence row 736 / evidence context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management. PubMed 40270953
Evidence class is insufficient.
Evidence row 737 / evidence context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Investigational cannabinoids in seizure disorders, what have we learned thus far? PubMed 29842819
Evidence class is insufficient.
Evidence row 739 / evidence context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
CB₁-independent mechanisms of Δ⁹-THCV, AM251 and SR141716 (rimonabant). PubMed 21740450
Evidence class is insufficient.
Evidence row 741 / evidence context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Ultrafast, Selective, and Highly Sensitive Nonchromatographic Analysis of Fourteen Cannabinoids in Cannabis Extracts, Δ8-Tetrahydrocannabinol Synthetic Mixtures, and Edibles by Cyclic Ion Mobility Spectrometry-Mass Spectrometry. PubMed 38862388
Evidence class is insufficient.
Evidence row 742 / evidence context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management. PubMed 40872492
Evidence class is insufficient.
Evidence row 743 / evidence context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review. PubMed 37630401
Evidence class is insufficient.
Evidence row 748 / evidence context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Prevalence of ∆8-tetrahydrocannabinol carboxylic acid in workplace drug testing. PubMed 37697897
Evidence class is insufficient.
Evidence row 749 / evidence context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Examining impairment and kinetic patterns associated with recent use of hemp-derived Δ8-tetrahydrocannabinol: case studies. PubMed 35799289
Evidence class is insufficient.
Evidence row 750 / evidence context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers. PubMed 25542687
Evidence class is insufficient.
Evidence row 753 / evidence context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Differences in Online Descriptions and Marketing of Derived Intoxicating Cannabis Products. PubMed 40131178
Evidence class is insufficient.
Evidence row 754 / evidence context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Role of Cannabidiol and Tetrahydrocannabivarin on Paclitaxel-induced neuropathic pain in rodents. PubMed 35303507
Evidence class is insufficient.
Evidence row 756 / evidence context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders. PubMed 31549358
Evidence class is insufficient.
Evidence row 757 / evidence context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabinoids and terpenes for diabetes mellitus and its complications: from mechanisms to new therapies. PubMed 36280497
Evidence class is insufficient.
Evidence row 758 / evidence context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Indeterminacy of cannabis impairment and ∆9-tetrahydrocannabinol (∆9-THC) levels in blood and breath. PubMed 35585089
Evidence class is insufficient.
Evidence row 759 / evidence context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile. PubMed 23894589
Evidence class is insufficient.
Evidence row 760 / evidence context
THCV modulates receptor, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets. PubMed 32899626
Evidence class is insufficient.
Evidence row 762 / evidence context
THCV modulates receptor, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management. PubMed 40872492
Evidence class is insufficient.
Evidence row 763 / evidence context
THCV modulates receptor, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. PubMed 17828291
Evidence class is insufficient.
Evidence row 766 / evidence context
THCV modulates receptor, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
Molecular Pharmacology of Phytocannabinoids. PubMed 28120231
Evidence class is insufficient.
Evidence row 767 / evidence context
THCV modulates receptor, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. PubMed 25257544
Evidence class is insufficient.
Evidence row 769 / evidence context
THCV modulates receptor, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
Pharmacology of cannabinoids in the treatment of epilepsy. PubMed 28087250
Evidence class is insufficient.
Evidence row 787 / evidence context
THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes.
insufficient / very_low confidence.
Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management. PubMed 40872492
Evidence class is insufficient.
Evidence row 790 / evidence context
THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes.
insufficient / very_low confidence.
Neuroimaging studies towards understanding the central effects of pharmacological cannabis products on patients with epilepsy. PubMed 28109780
Evidence class is insufficient.
Evidence row 792 / evidence context
THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes.
insufficient / very_low confidence.
Medical use of cannabis. Cannabidiol: a new light for schizophrenia? PubMed 23109356
Evidence class is insufficient.
Evidence row 794 / evidence context
THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes.
insufficient / very_low confidence.
Molecular pathway and structural mechanism of human oncochannel TRPV6 inhibition by the phytocannabinoid tetrahydrocannabivarin. PubMed 37532722
Evidence class is insufficient.
Evidence row 796 / evidence context
THCV studied for Pain-related outcomes.
insufficient / very_low confidence.
It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets. PubMed 32899626
Evidence class is insufficient.
Evidence row 805 / evidence context
THCV studied for Pain-related outcomes.
insufficient / very_low confidence.
The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. PubMed 22155112
Evidence class is insufficient.
Evidence row 806 / evidence context
Cannabinoids modulates CB1.
insufficient / very_low confidence.
Oxa-adamantyl cannabinoids. PubMed 33636308
Evidence class is insufficient.
Evidence row 807 / evidence context
Cannabinoids modulates CB1.
insufficient / very_low confidence.
Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists. PubMed 18537620
Evidence class is insufficient.
Evidence row 808 / evidence context
THC modulates CB1.
insufficient / very_low confidence.
Pharmacological actions of cannabinoids. PubMed 16596770
Evidence class is insufficient.
Evidence row 813 / evidence context
Cannabinoids modulates CB1.
insufficient / very_low confidence.
Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities. PubMed 28527758
Evidence class is insufficient.
Evidence row 814 / evidence context
Endocannabinoids modulates CB1.
insufficient / very_low confidence.
Cannabinergic ligands. PubMed 12505686
Evidence class is insufficient.
Evidence row 817 / evidence context
Cannabinoids modulates CB1.
insufficient / very_low confidence.
Pharmacology of cannabinoid receptor ligands. PubMed 10469884
Evidence class is insufficient.
Evidence row 818 / evidence context
Endocannabinoids modulates CB1.
insufficient / very_low confidence.
Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor. PubMed 27879006
Evidence class is insufficient.
Evidence row 819 / evidence context
Cannabinoids modulates CB1.
insufficient / very_low confidence.
The CB1 cannabinoid receptor in the brain. PubMed 9974174
Evidence class is insufficient.
Evidence row 820 / evidence context
Cannabinoids modulates CB1.
insufficient / very_low confidence.
CB1 Cannabinoid Receptor Signaling and Biased Signaling. PubMed 34500853
Evidence class is insufficient.
Evidence row 821 / evidence context
Cannabinoids modulates CB1.
insufficient / very_low confidence.
Translational potential of allosteric modulators targeting the cannabinoid CB1 receptor. PubMed 30333554
Evidence class is insufficient.
Evidence row 827 / evidence context
Endocannabinoids modulates CB1.
insufficient / very_low confidence.
Endocannabinoids and Their Pharmacological Actions. PubMed 26408156
Evidence class is insufficient.
Evidence row 831 / evidence context
Cannabinoids modulates CB1.
insufficient / very_low confidence.
Allosteric modulators of cannabinoid receptor 1: developing compounds for improved specificity. PubMed 29355030
Evidence class is insufficient.
Evidence row 832 / evidence context
THC modulates CB1.
insufficient / very_low confidence.
Synthetic Cannabinoids. PubMed 26132518
Evidence class is insufficient.
Evidence row 833 / evidence context
Endocannabinoids modulates CB1.
insufficient / very_low confidence.
Cannabinoid receptor 1 ligands: Biased signaling mechanisms driving functionally selective drug discovery. PubMed 39828030
Evidence class is insufficient.
Evidence row 837 / evidence context
THC modulates CB1.
insufficient / very_low confidence.
Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists. PubMed 33811300
Evidence class is insufficient.
Evidence row 838 / evidence context
Cannabinoids modulates CB1.
insufficient / very_low confidence.
Computational Analysis of Dipyrone Metabolite 4-Aminoantipyrine As A Cannabinoid Receptor 1 Agonist. PubMed 31490743
Evidence class is insufficient.
Evidence row 839 / evidence context
Cannabinoids modulates CB1.
insufficient / very_low confidence.
New Insights in Cannabinoid Receptor Structure and Signaling. PubMed 30767756
Evidence class is insufficient.
Evidence row 840 / evidence context
Cannabinoids modulates CB1.
insufficient / very_low confidence.
Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities. PubMed 28527758
Evidence class is insufficient.
Evidence row 841 / evidence context
Cannabinoids modulates CB1.
insufficient / very_low confidence.
Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery? PubMed 20590557
Evidence class is insufficient.
Evidence row 842 / evidence context
Endocannabinoids modulates CB1.
insufficient / very_low confidence.
Cannabinoid-based therapy as a future for joint degeneration. Focus on the role of CB2 receptor in the arthritis progression and pain: an updated review. PubMed 34050525
Evidence class is insufficient.
Evidence row 843 / evidence context
THC modulates CB1.
insufficient / very_low confidence.
Endocannabinoid System: A Multi-Facet Therapeutic Target. PubMed 27086601
Evidence class is insufficient.
Evidence row 845 / evidence context
Cannabinoids modulates CB1.
insufficient / very_low confidence.
Allosteric Modulation of Cannabinoid Receptor 1-Current Challenges and Future Opportunities. PubMed 31771126
Evidence class is insufficient.
Evidence row 846 / evidence context
Endocannabinoids modulates CB1.
insufficient / very_low confidence.
The pharmacology of cannabinoid receptors and their ligands: an overview. PubMed 16570099
Evidence class is insufficient.
Evidence row 847 / evidence context
Endocannabinoids modulates CB1.
insufficient / very_low confidence.
Latest advances in cannabinoid receptor agonists. PubMed 19939187
Evidence class is insufficient.
Evidence row 848 / evidence context
THC modulates CB1.
insufficient / very_low confidence.
Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. PubMed 19285266
Evidence class is insufficient.
Evidence row 849 / evidence context
Endocannabinoids modulates CB1.
insufficient / very_low confidence.
Therapeutic potential of cannabinoid receptor 2 in the treatment of diabetes mellitus and its complications. PubMed 31461639
Evidence class is insufficient.
Evidence row 850 / evidence context
Endocannabinoids modulates CB1.
insufficient / very_low confidence.
The endocannabinoid system: physiology and pharmacology. PubMed 15550444
Evidence class is insufficient.
Evidence row 855 / evidence context
Endocannabinoids modulates CB1.
insufficient / very_low confidence.
Astroglial type-1 cannabinoid receptor (CB1): A new player in the tripartite synapse. PubMed 25967266
Evidence class is insufficient.
Evidence row 858 / evidence context
THC modulates CB1.
insufficient / very_low confidence.
The effects of cannabinoid 1 receptor compounds on memory: a meta-analysis and systematic review across species. PubMed 31165913
Evidence class is insufficient.
Evidence row 862 / evidence context
Endocannabinoids modulates CB1.
insufficient / very_low confidence.
Analysis of the endocannabinoid system by using CB1 cannabinoid receptor knockout mice. PubMed 16596773
Evidence class is insufficient.
Evidence row 863 / evidence context
THC modulates CB2.
insufficient / very_low confidence.
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. PubMed 17828291
Evidence class is insufficient.
Evidence row 864 / evidence context
Cannabinoids modulates CB2.
insufficient / very_low confidence.
Cannabinoid receptor 2 (CB2) modulators: A patent review (2016-2024). PubMed 39288632
Evidence class is insufficient.
Evidence row 865 / evidence context
Cannabinoids modulates CB2.
insufficient / very_low confidence.
Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists. PubMed 18537620
Evidence class is insufficient.
Evidence row 866 / evidence context
THC modulates CB2.
insufficient / very_low confidence.
An Introduction to the Endogenous Cannabinoid System. PubMed 26698193
Evidence class is insufficient.
Evidence row 868 / evidence context
Endocannabinoids modulates CB2.
insufficient / very_low confidence.
Cannabinergic ligands. PubMed 12505686
Evidence class is insufficient.
Evidence row 869 / evidence context
Cannabinoids modulates CB2.
insufficient / very_low confidence.
Pharmacology of cannabinoid receptor ligands. PubMed 10469884
Evidence class is insufficient.
Evidence row 870 / evidence context
THC modulates CB2.
insufficient / very_low confidence.
Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists. PubMed 33811300
Evidence class is insufficient.
Evidence row 872 / evidence context
Endocannabinoids modulates CB2.
insufficient / very_low confidence.
Functional Selectivity at Cannabinoid Receptors. PubMed 28826535
Evidence class is insufficient.
Evidence row 873 / evidence context
Cannabinoids modulates CB2.
insufficient / very_low confidence.
Pharmacology of cannabinoid CB1 and CB2 receptors. PubMed 9336020
Evidence class is insufficient.
Evidence row 875 / evidence context
Cannabinoids modulates CB2.
insufficient / very_low confidence.
The Spicy Story of Cannabimimetic Indoles. PubMed 34684770
Evidence class is insufficient.
Evidence row 882 / evidence context
Cannabinoids modulates CB2.
insufficient / very_low confidence.
Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update. PubMed 27215781
Evidence class is insufficient.
Evidence row 889 / evidence context
Endocannabinoids modulates CB2.
insufficient / very_low confidence.
Patent review of cannabinoid receptor type 2 (CB2R) modulators (2016-present). PubMed 38886185
Evidence class is insufficient.
Evidence row 890 / evidence context
Anandamide modulates CB2.
insufficient / very_low confidence.
Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. PubMed 16678907
Evidence class is insufficient.
Evidence row 891 / evidence context
Cannabinoids modulates CB2.
insufficient / very_low confidence.
Cannabinoid CB2 receptor orthologues; in vitro function and perspectives for preclinical to clinical translation. PubMed 37349984
Evidence class is insufficient.
Evidence row 892 / evidence context
Endocannabinoids modulates CB2.
insufficient / very_low confidence.
Recent Advances on Type-2 Cannabinoid (CB2) Receptor Agonists and their Therapeutic Potential. PubMed 36028971
Evidence class is insufficient.
Evidence row 893 / evidence context
THC modulates CB2.
insufficient / very_low confidence.
The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances: Origins. PubMed 29980914
Evidence class is insufficient.
Evidence row 894 / evidence context
Anandamide modulates CB2.
insufficient / very_low confidence.
Structural requirements for cannabinoid receptor probes. PubMed 16596776
Evidence class is insufficient.
Evidence row 896 / evidence context
Cannabinoids modulates CB2.
insufficient / very_low confidence.
Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. PubMed 19152719
Evidence class is insufficient.
Evidence row 898 / evidence context
Cannabinoids modulates CB2.
insufficient / very_low confidence.
CB₂: therapeutic target-in-waiting. PubMed 22197668
Evidence class is insufficient.
Evidence row 900 / evidence context
Endocannabinoids modulates CB2.
insufficient / very_low confidence.
Emerging roles of cannabinoid receptor CB2 receptor in the central nervous system: therapeutic target for CNS disorders. PubMed 39264450
Evidence class is insufficient.
Evidence row 905 / evidence context
Cannabinoids modulates CB2.
insufficient / very_low confidence.
An overview of the cannabinoid type 2 receptor system and its therapeutic potential. PubMed 29794855
Evidence class is insufficient.
Evidence row 910 / evidence context
Cannabinoids modulates CB2.
insufficient / very_low confidence.
The development of cannabinoid CBII receptor agonists for the treatment of central neuropathies. PubMed 20236042
Evidence class is insufficient.
Evidence row 917 / evidence context
Endocannabinoids modulates CB2.
insufficient / very_low confidence.
What we know and do not know about the cannabinoid receptor 2 (CB2). PubMed 24877594
Evidence class is insufficient.
Evidence row 919 / evidence context
Cannabinoids modulates CB2.
insufficient / very_low confidence.
Cannabinoid Receptor 2 (CB2) in Macrophages: A Promising Clinical Target for Immune Disorders. PubMed 40943579
Evidence class is insufficient.
Evidence row 923 / evidence context
Cannabinoids modulates CB2.
insufficient / very_low confidence.
Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection? PubMed 32471272
Evidence class is insufficient.
Evidence row 926 / evidence context
Cannabinoids modulates GPR55.
insufficient / very_low confidence.
Cannabinoid Receptor-Related Orphan G Protein-Coupled Receptors. PubMed 28826536
Evidence class is insufficient.
Evidence row 927 / evidence context
THC modulates GPR55.
insufficient / very_low confidence.
Cannabinoids in the landscape of cancer. PubMed 34259916
Evidence class is insufficient.
Evidence row 928 / evidence context
Cannabinoids modulates GPR55.
insufficient / very_low confidence.
The enigmatic pharmacology of GPR55. PubMed 19233486
Evidence class is insufficient.
Evidence row 929 / evidence context
Endocannabinoids modulates GPR55.
insufficient / very_low confidence.
Molecular networks underlying cannabinoid signaling in skeletal muscle plasticity. PubMed 35862111
Evidence class is insufficient.
Evidence row 930 / evidence context
Endocannabinoids modulates GPR55.
insufficient / very_low confidence.
Is GPR55 an anandamide receptor? PubMed 19647110
Evidence class is insufficient.
Evidence row 932 / evidence context
Cannabinoids modulates GPR55.
insufficient / very_low confidence.
GPR55 - a putative "type 3" cannabinoid receptor in inflammation. PubMed 26669245
Evidence class is insufficient.
Evidence row 933 / evidence context
Cannabinoids modulates GPR55.
insufficient / very_low confidence.
Cannabinoid receptor ligand bias: implications in the central nervous system. PubMed 27835801
Evidence class is insufficient.
Evidence row 934 / evidence context
Cannabinoids modulates GPR55.
insufficient / very_low confidence.
GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity? PubMed 20370712
Evidence class is insufficient.
Evidence row 935 / evidence context
CBD modulates GPR55.
insufficient / very_low confidence.
A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD). PubMed 35083862
Evidence class is insufficient.
Evidence row 937 / evidence context
Endocannabinoids modulates GPR55.
insufficient / very_low confidence.
The Endocannabinoid System of Animals. PubMed 31527410
Evidence class is insufficient.
Evidence row 938 / evidence context
THC modulates GPR55.
insufficient / very_low confidence.
GPR55: a new member of the cannabinoid receptor clan? PubMed 17876300
Evidence class is insufficient.
Evidence row 939 / evidence context
THC modulates GPR55.
insufficient / very_low confidence.
Pharmacological characterization of GPR55, a putative cannabinoid receptor. PubMed 20298715
Evidence class is insufficient.
Evidence row 941 / evidence context
Endocannabinoids modulates GPR55.
insufficient / very_low confidence.
Cannabis and Endocannabinoid Signaling in Epilepsy. PubMed 26408165
Evidence class is insufficient.
Evidence row 942 / evidence context
CBD modulates GPR55.
insufficient / very_low confidence.
Epilepsy, neuroinflammation and cannabidiol What do we know thus far? PubMed 41560741
Evidence class is insufficient.
Evidence row 944 / evidence context
Cannabinoids modulates GPR18.
insufficient / very_low confidence.
Cannabinoid Receptor-Related Orphan G Protein-Coupled Receptors. PubMed 28826536
Evidence class is insufficient.
Evidence row 945 / evidence context
Cannabinoids modulates GPR18.
insufficient / very_low confidence.
Cannabinoid receptor ligand bias: implications in the central nervous system. PubMed 27835801
Evidence class is insufficient.
Evidence row 947 / evidence context
Endocannabinoids modulates GPR18.
insufficient / very_low confidence.
Cannabinoids in Gynecological Diseases. PubMed 34676329
Evidence class is insufficient.
Evidence row 948 / evidence context
Endocannabinoids modulates GPR18.
insufficient / very_low confidence.
Targeting GPR18: Structural modelling, ligand discovery, and therapeutic potential in neuroinflammatory disorders. PubMed 42114685
Evidence class is insufficient.
Evidence row 952 / evidence context
Endocannabinoids modulates GPR18.
insufficient / very_low confidence.
An Update on Non-CB1, Non-CB2 Cannabinoid Related G-Protein-Coupled Receptors. PubMed 29098189
Evidence class is insufficient.
Evidence row 958 / evidence context
Endocannabinoids modulates GPR18.
insufficient / very_low confidence.
N-Acyl Amino Acids (Elmiric Acids): Endogenous Signaling Molecules with Therapeutic Potential. PubMed 29138268
Evidence class is insufficient.
Evidence row 961 / evidence context
Endocannabinoids modulates GPR18.
insufficient / very_low confidence.
The elmiric acids: biologically active anandamide analogs. PubMed 18187165
Evidence class is insufficient.
Evidence row 963 / evidence context
Endocannabinoids modulates GPR119.
insufficient / very_low confidence.
Endocannabinoids and nutrition. PubMed 18426507
Evidence class is insufficient.
Evidence row 964 / evidence context
Anandamide modulates GPR119.
insufficient / very_low confidence.
N-acylethanolamines, anandamide and food intake. PubMed 19413995
Evidence class is insufficient.
Evidence row 965 / evidence context
Anandamide modulates GPR119.
insufficient / very_low confidence.
Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. PubMed 20353771
Evidence class is insufficient.
Evidence row 966 / evidence context
Endocannabinoids modulates GPR119.
insufficient / very_low confidence.
Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance. PubMed 19285259
Evidence class is insufficient.
Evidence row 969 / evidence context
Endocannabinoids modulates GPR119.
insufficient / very_low confidence.
Fatty acid amide hydrolase (FAAH) and the endocannabinoid system in obesity: Mechanistic insights and pharmacological opportunities beyond incretin-based therapies. PubMed 42144898
Evidence class is insufficient.
Evidence row 970 / evidence context
Endocannabinoids modulates GPR119.
insufficient / very_low confidence.
Oleoylethanolamide: A novel pharmaceutical agent in the management of obesity-an updated review. PubMed 30537148
Evidence class is insufficient.
Evidence row 971 / evidence context
THC modulates TRPV1.
insufficient / very_low confidence.
Cannabinoid Ligands Targeting TRP Channels. PubMed 30697147
Evidence class is insufficient.
Evidence row 972 / evidence context
THC modulates TRPV1.
insufficient / very_low confidence.
Cannabinoids in the landscape of cancer. PubMed 34259916
Evidence class is insufficient.
Evidence row 973 / evidence context
THC modulates TRPV1.
insufficient / very_low confidence.
Pharmacological actions of cannabinoids. PubMed 16596770
Evidence class is insufficient.
Evidence row 975 / evidence context
Cannabinoids modulates TRPV1.
insufficient / very_low confidence.
Cannabinoid signalling. PubMed 16109430
Evidence class is insufficient.
Evidence row 976 / evidence context
THC modulates TRPV1.
insufficient / very_low confidence.
Cannabinoids and anxiety. PubMed 21309120
Evidence class is insufficient.
Evidence row 977 / evidence context
OEA modulates TRPV1.
insufficient / very_low confidence.
Novel cannabinoid receptors. PubMed 17906678
Evidence class is insufficient.
Evidence row 979 / evidence context
Anandamide modulates TRPV1.
insufficient / very_low confidence.
TRPV1 Channel: A Potential Drug Target for Treating Epilepsy. PubMed 26411767
Evidence class is insufficient.
Evidence row 980 / evidence context
Endocannabinoids modulates TRPV1.
insufficient / very_low confidence.
Endocannabinoid signaling in microglia. PubMed 36222019
Evidence class is insufficient.
Evidence row 981 / evidence context
Cannabinoids modulates TRPV1.
insufficient / very_low confidence.
Modulation of TRPV1 channel function by natural products in the treatment of pain. PubMed 32738201
Evidence class is insufficient.
Evidence row 983 / evidence context
CBD modulates TRPV1.
insufficient / very_low confidence.
Cannabidiol improves L-DOPA-induced dyskinesia and modulates neuroinflammation and the endocannabinoid, endovanilloid and nitrergic systems. PubMed 40684872
Evidence class is insufficient.
Evidence row 984 / evidence context
THC modulates TRPV1.
insufficient / very_low confidence.
Exploiting cannabinoid and vanilloid mechanisms for epilepsy treatment. PubMed 31839498
Evidence class is insufficient.
Evidence row 985 / evidence context
THC modulates TRPV1.
insufficient / very_low confidence.
Cannabis for the Treatment of Epilepsy: an Update. PubMed 30194563
Evidence class is insufficient.
Evidence row 986 / evidence context
THC modulates TRPV1.
insufficient / very_low confidence.
Cannabis and the exocannabinoid and endocannabinoid systems. Their use and controversies. PubMed 32091020
Evidence class is insufficient.
Evidence row 987 / evidence context
Endocannabinoids modulates TRPV1.
insufficient / very_low confidence.
Beyond Cannabis: Plants and the Endocannabinoid System. PubMed 27179600
Evidence class is insufficient.
Evidence row 988 / evidence context
THC modulates TRPV1.
insufficient / very_low confidence.
Cannabis y los sistemas exocannabinoide y endocannabinoide. Su uso y controversias. PubMed 31695229
Evidence class is insufficient.
Evidence row 989 / evidence context
THC modulates TRPV2.
insufficient / very_low confidence.
Cannabinoid Ligands Targeting TRP Channels. PubMed 30697147
Evidence class is insufficient.
Evidence row 990 / evidence context
THC modulates TRPV2.
insufficient / very_low confidence.
Cannabinoids in the landscape of cancer. PubMed 34259916
Evidence class is insufficient.
Evidence row 995 / evidence context
THC modulates TRPV2.
insufficient / very_low confidence.
Cannabidiol interactions with voltage-gated sodium channels. PubMed 33089780
Evidence class is insufficient.
Evidence row 996 / evidence context
THC modulates TRPV2.
insufficient / very_low confidence.
Iodine-Promoted Aromatization of p-Menthane-Type Phytocannabinoids. PubMed 29240420
Evidence class is insufficient.
Evidence row 997 / evidence context
Cannabinoids modulates TRPV2.
insufficient / very_low confidence.
Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia. PubMed 19070372
Evidence class is insufficient.
Evidence row 1004 / evidence context
THC modulates TRPV3.
insufficient / very_low confidence.
Cannabinoid Ligands Targeting TRP Channels. PubMed 30697147
Evidence class is insufficient.
Evidence row 1005 / evidence context
CBD modulates TRPV3.
insufficient / very_low confidence.
An Analysis of the Putative CBD Binding Site in the Ionotropic Cannabinoid Receptors. PubMed 33362478
Evidence class is insufficient.
Evidence row 1011 / evidence context
Cannabinoids modulates TRPV3.
insufficient / very_low confidence.
Pharmacogenetics of new analgesics. PubMed 20942817
Evidence class is insufficient.
Evidence row 1014 / evidence context
Cannabinoids modulates TRPV3.
insufficient / very_low confidence.
A Systematic Review of Plant-Derived Natural Compounds for Anxiety Disorders. PubMed 26845556
Evidence class is insufficient.
Evidence row 1016 / evidence context
THC modulates TRPV4.
insufficient / very_low confidence.
Cannabinoid Ligands Targeting TRP Channels. PubMed 30697147
Evidence class is insufficient.
Evidence row 1017 / evidence context
CBD modulates TRPV4.
insufficient / very_low confidence.
An Analysis of the Putative CBD Binding Site in the Ionotropic Cannabinoid Receptors. PubMed 33362478
Evidence class is insufficient.
Evidence row 1020 / evidence context
Cannabinoids modulates TRPV4.
insufficient / very_low confidence.
Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia. PubMed 19070372
Evidence class is insufficient.
Evidence row 1024 / evidence context
Cannabinoids modulates TRPV4.
insufficient / very_low confidence.
Toward an effective peripheral visceral analgesic: responding to the national opioid crisis. PubMed 29470146
Evidence class is insufficient.
Evidence row 1025 / evidence context
Endocannabinoids modulates TRPV4.
insufficient / very_low confidence.
Potential Future Pharmacological Treatment of Bladder Dysfunction. PubMed 26990140
Evidence class is insufficient.
Evidence row 1029 / evidence context
CBD modulates TRPV4.
insufficient / very_low confidence.
Mechanisms of Cell Death Induced by Cannabidiol Against Tumor Cells: A Review of Preclinical Studies. PubMed 40006844
Evidence class is insufficient.
Evidence row 1030 / evidence context
THC modulates TRPA1.
insufficient / very_low confidence.
Cannabinoid Ligands Targeting TRP Channels. PubMed 30697147
Evidence class is insufficient.
Evidence row 1031 / evidence context
CBD modulates TRPA1.
insufficient / very_low confidence.
Pharmacological effects of cannabidiol by transient receptor potential channels. PubMed 35483477
Evidence class is insufficient.
Evidence row 1032 / evidence context
THC modulates TRPA1.
insufficient / very_low confidence.
Cannabinoids in the landscape of cancer. PubMed 34259916
Evidence class is insufficient.
Evidence row 1033 / evidence context
THC modulates TRPA1.
insufficient / very_low confidence.
Iodine-Promoted Aromatization of p-Menthane-Type Phytocannabinoids. PubMed 29240420
Evidence class is insufficient.
Evidence row 1034 / evidence context
Cannabinoids modulates TRPA1.
insufficient / very_low confidence.
Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia. PubMed 19070372
Evidence class is insufficient.
Evidence row 1036 / evidence context
Cannabinoids modulates TRPA1.
insufficient / very_low confidence.
TRPA1. PubMed 24756722
Evidence class is insufficient.
Evidence row 1039 / evidence context
THC modulates TRPA1.
insufficient / very_low confidence.
Molecular Targets of the Phytocannabinoids: A Complex Picture. PubMed 28120232
Evidence class is insufficient.
Evidence row 1040 / evidence context
Cannabinoids modulates TRPA1.
insufficient / very_low confidence.
G-protein coupled receptors regulating cough. PubMed 21727026
Evidence class is insufficient.
Evidence row 1044 / evidence context
CBD modulates TRPA1.
insufficient / very_low confidence.
Myrcene and terpene regulation of TRPV1. PubMed 31446830
Evidence class is insufficient.
Evidence row 1045 / evidence context
CBD modulates TRPA1.
insufficient / very_low confidence.
Systematic Review on Transdermal/Topical Cannabidiol Trials: A Reconsidered Way Forward. PubMed 35605018
Evidence class is insufficient.
Evidence row 1048 / evidence context
CBD modulates TRPM8.
insufficient / very_low confidence.
Pharmacological effects of cannabidiol by transient receptor potential channels. PubMed 35483477
Evidence class is insufficient.
Evidence row 1053 / evidence context
THC modulates TRPM8.
insufficient / very_low confidence.
Iodine-Promoted Aromatization of p-Menthane-Type Phytocannabinoids. PubMed 29240420
Evidence class is insufficient.
Evidence row 1054 / evidence context
Cannabinoids modulates TRPM8.
insufficient / very_low confidence.
Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia. PubMed 19070372
Evidence class is insufficient.
Evidence row 1055 / evidence context
Cannabinoids modulates TRPM8.
insufficient / very_low confidence.
Toward an effective peripheral visceral analgesic: responding to the national opioid crisis. PubMed 29470146
Evidence class is insufficient.
Evidence row 1056 / evidence context
THC modulates TRPM8.
insufficient / very_low confidence.
Molecular Targets of the Phytocannabinoids: A Complex Picture. PubMed 28120232
Evidence class is insufficient.
Evidence row 1057 / evidence context
CBD modulates TRPM8.
insufficient / very_low confidence.
Systematic Review on Transdermal/Topical Cannabidiol Trials: A Reconsidered Way Forward. PubMed 35605018
Evidence class is insufficient.
Evidence row 1060 / evidence context
Cannabinoids modulates TRPM8.
insufficient / very_low confidence.
Effects of opioids, cannabinoids, and vanilloids on body temperature. PubMed 21622235
Evidence class is insufficient.
Evidence row 1063 / evidence context
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities. PubMed 36150527
Evidence class is insufficient.
Evidence row 1064 / evidence context
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Metabolism of endocannabinoids. PubMed 27516570
Evidence class is insufficient.
Evidence row 1065 / evidence context
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Anandamide uptake explained? PubMed 22297258
Evidence class is insufficient.
Evidence row 1066 / evidence context
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Anandamide receptors. PubMed 12052051
Evidence class is insufficient.
Evidence row 1068 / evidence context
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Endocannabinoid metabolism by cytochrome P450 monooxygenases. PubMed 25461979
Evidence class is insufficient.
Evidence row 1069 / evidence context
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Endocannabinoids and pregnancy. PubMed 20302856
Evidence class is insufficient.
Evidence row 1070 / evidence context
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Anandamide and its metabolites: what are their roles in the kidney? PubMed 27100705
Evidence class is insufficient.
Evidence row 1074 / evidence context
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Targeting Endocannabinoid Signaling: FAAH and MAG Lipase Inhibitors. PubMed 32867595
Evidence class is insufficient.
Evidence row 1075 / evidence context
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Druggable Targets in Endocannabinoid Signaling. PubMed 32894511
Evidence class is insufficient.
Evidence row 1076 / evidence context
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Chemical probes of endocannabinoid metabolism. PubMed 23512546
Evidence class is insufficient.
Evidence row 1077 / evidence context
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Amygdala FAAH and anandamide: mediating protection and recovery from stress. PubMed 24325918
Evidence class is insufficient.
Evidence row 1078 / evidence context
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
The Endocannabinoid System and its Modulation by Phytocannabinoids. PubMed 26271952
Evidence class is insufficient.
Evidence row 1079 / evidence context
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors. PubMed 21418147
Evidence class is insufficient.
Evidence row 1080 / evidence context
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Cannabinergic ligands. PubMed 12505686
Evidence class is insufficient.
Evidence row 1081 / evidence context
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. PubMed 16678907
Evidence class is insufficient.
Evidence row 1082 / evidence context
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Endocannabinoid overload. PubMed 20952498
Evidence class is insufficient.
Evidence row 1083 / evidence context
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Endocannabinoid hydrolases. PubMed 12432941
Evidence class is insufficient.
Evidence row 1086 / evidence context
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Inhibiting degradation of 2-arachidonoylglycerol as a therapeutic strategy for neurodegenerative diseases. PubMed 36966972
Evidence class is insufficient.
Evidence row 1090 / evidence context
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Chemical approaches to therapeutically target the metabolism and signaling of the endocannabinoid 2-AG and eicosanoids. PubMed 24676249
Evidence class is insufficient.
Evidence row 1092 / evidence context
OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Endocannabinoids and nutrition. PubMed 18426507
Evidence class is insufficient.
Evidence row 1093 / evidence context
OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
N-acylethanolamines, anandamide and food intake. PubMed 19413995
Evidence class is insufficient.
Evidence row 1094 / evidence context
OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance. PubMed 19285259
Evidence class is insufficient.
Evidence row 1095 / evidence context
OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Oleoylethanolamide: A novel pharmaceutical agent in the management of obesity-an updated review. PubMed 30537148
Evidence class is insufficient.
Evidence row 1096 / evidence context
OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
A fatty gut feeling. PubMed 23567058
Evidence class is insufficient.
Evidence row 1098 / evidence context
OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Regulation of food intake by oleoylethanolamide. PubMed 15770421
Evidence class is insufficient.
Evidence row 1099 / evidence context
OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
The endocannabinoid and paracannabinoid systems in natural reward processes: possible pharmacological targets? PubMed 40274041
Evidence class is insufficient.
Evidence row 1100 / evidence context
OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Brain molecules and appetite: the case of oleoylethanolamide. PubMed 23464987
Evidence class is insufficient.
Evidence row 1104 / evidence context
OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Regulation of Cholesterol and Triglyceride Metabolism by Fatty acid Ethanolamides. PubMed 42068417
Evidence class is insufficient.
Evidence row 1105 / evidence context
OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Investigation the effect of oleoylethanolamide supplementation on the abundance of Akkermansia muciniphila bacterium and the dietary intakes in people with obesity: A randomized clinical trial. PubMed 31132422
Evidence class is insufficient.
Evidence row 1107 / evidence context
PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms.
insufficient / very_low confidence.
Mechanisms and clinical applications of palmitoylethanolamide (PEA) in the treatment of neuropathic pain. PubMed 39714723
Evidence class is insufficient.
Evidence row 1108 / evidence context
PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms.
insufficient / very_low confidence.
The search for the palmitoylethanolamide receptor. PubMed 15963531
Evidence class is insufficient.
Evidence row 1111 / evidence context
PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms.
insufficient / very_low confidence.
Gut-brain Axis: Role of Lipids in the Regulation of Inflammation, Pain and CNS Diseases. PubMed 28215162
Evidence class is insufficient.
Evidence row 1112 / evidence context
PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms.
insufficient / very_low confidence.
Cannabimimetic fatty acid derivatives in cancer and inflammation. PubMed 10785541
Evidence class is insufficient.
Evidence row 1114 / evidence context
PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms.
insufficient / very_low confidence.
Palmitoylethanolamide and Its Biobehavioral Correlates in Autism Spectrum Disorder: A Systematic Review of Human and Animal Evidence. PubMed 33919499
Evidence class is insufficient.
Evidence row 1115 / evidence context
PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms.
insufficient / very_low confidence.
Targeting inflammation: new therapeutic approaches in chronic kidney disease (CKD). PubMed 24602801
Evidence class is insufficient.
Evidence row 1116 / evidence context
PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms.
insufficient / very_low confidence.
Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with trauma. PubMed 22697514
Evidence class is insufficient.
Evidence row 1119 / evidence context
Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms.
insufficient / very_low confidence.
Endocannabinoid hydrolases. PubMed 12432941
Evidence class is insufficient.
Evidence row 1120 / evidence context
Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms.
insufficient / very_low confidence.
Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications. PubMed 11945157
Evidence class is insufficient.
Evidence row 1121 / evidence context
Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms.
insufficient / very_low confidence.
Oleamide: a member of the endocannabinoid family? PubMed 14691053
Evidence class is insufficient.
Evidence row 1122 / evidence context
Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms.
insufficient / very_low confidence.
Oleamide: a fatty acid amide signaling molecule in the cardiovascular system? PubMed 17445087
Evidence class is insufficient.
Evidence row 1123 / evidence context
Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms.
insufficient / very_low confidence.
The palmitoylethanolamide and oleamide enigmas : are these two fatty acid amides cannabimimetic? PubMed 10469890
Evidence class is insufficient.
Evidence row 1124 / evidence context
Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms.
insufficient / very_low confidence.
The role of the CB1 receptor in the regulation of sleep. PubMed 18514375
Evidence class is insufficient.
Evidence row 1126 / evidence context
Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms.
insufficient / very_low confidence.
The enzymatic inactivation of the fatty acid amide class of signaling lipids. PubMed 12505696
Evidence class is insufficient.
Evidence row 1127 / evidence context
Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms.
insufficient / very_low confidence.
Oleamide: an endogenous sleep-inducing lipid and prototypical member of a new class of biological signaling molecules. PubMed 10197045
Evidence class is insufficient.
Evidence row 1131 / evidence context
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
N-Arachidonoyl Dopamine: A Novel Endocannabinoid and Endovanilloid with Widespread Physiological and Pharmacological Activities. PubMed 29082315
Evidence class is insufficient.
Evidence row 1144 / evidence context
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Endocannabinoids and Their Pharmacological Actions. PubMed 26408156
Evidence class is insufficient.
Evidence row 1146 / evidence context
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
The cannabinoid receptors. PubMed 12432948
Evidence class is insufficient.
Evidence row 1156 / evidence context
Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Endocannabinoids and Their Pharmacological Actions. PubMed 26408156
Evidence class is insufficient.
Evidence row 1157 / evidence context
Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
GPR55: a new member of the cannabinoid receptor clan? PubMed 17876300
Evidence class is insufficient.
Evidence row 1158 / evidence context
Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
The role of the CB1 receptor in the regulation of sleep. PubMed 18514375
Evidence class is insufficient.
Evidence row 1167 / evidence context
DHEA / synaptamide studied for DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Synaptamide, endocannabinoid-like derivative of docosahexaenoic acid with cannabinoid-independent function. PubMed 22959887
Evidence class is insufficient.
Evidence row 1171 / evidence context
DHEA / synaptamide studied for DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
A synaptogenic amide N-docosahexaenoylethanolamide promotes hippocampal development. PubMed 21810478
Evidence class is insufficient.
Evidence row 1172 / evidence context
LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Classical endocannabinoid-like compounds and their regulation by nutrients. PubMed 24677570
Evidence class is insufficient.
Evidence row 1174 / evidence context
LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Role of anorectic N-acylethanolamines in intestinal physiology and satiety control with respect to dietary fat. PubMed 24681513
Evidence class is insufficient.
Evidence row 1180 / evidence context
LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Gene Expression of Endocannabinoid System Components in Skeletal Muscle and Adipose Tissue of South Asians and White Caucasians with Overweight. PubMed 30070030
Evidence class is insufficient.
Evidence row 1181 / evidence context
LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. PubMed 11463796
Evidence class is insufficient.
Evidence row 1186 / evidence context
SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. PubMed 20353771
Evidence class is insufficient.
Evidence row 1188 / evidence context
SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Roles of fatty acid ethanolamides (FAE) in traumatic and ischemic brain injury. PubMed 24874648
Evidence class is insufficient.
Evidence row 1195 / evidence context
SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Lipidomic Analysis of Endocannabinoid Signaling: Targeted Metabolite Identification and Quantification. PubMed 26839710
Evidence class is insufficient.
Evidence row 1197 / evidence context
SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator. PubMed 23813098
Evidence class is insufficient.
Evidence row 1202 / evidence context
Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms.
insufficient / very_low confidence.
Cannabinoids and Sleep/Wake Control. PubMed 33537938
Evidence class is insufficient.
Source-Backed Connections
Related pages in the current encyclopedia
No source-backed public page is linked to this term in the current launch set yet. Start with the evidence method, then add sources as the term page matures.
Nearby Terms